


REVIEW

Open Access



Platelet integrin α IIb β 3: signal transduction, regulation, and its therapeutic targeting

Jiansong Huang^{1,2,3†}, Xia Li^{1,2,3†}, Xiaofeng Shi⁴, Mark Zhu¹, Jinghan Wang^{1,2,3}, Shujuan Huang^{1,2,3}, Xin Huang^{1,2,3}, Huafeng Wang^{1,2,3,5}, Ling Li⁵, Huan Deng⁶, Yulan Zhou⁷, Jianhua Mao^{8,9}, Zhangbiao Long¹⁰, Zhixin Ma¹¹, Wenle Ye^{1,2,3}, Jiajia Pan^{1,2,3}, Xiaodong Xi^{8,9*} and Jie Jin^{1,2,3*} 

Abstract

Integrins are a family of transmembrane glycoprotein signaling receptors that can transmit bioinformation bidirectionally across the plasma membrane. Integrin α IIb β 3 is expressed at a high level in platelets and their progenitors, where it plays a central role in platelet functions, hemostasis, and arterial thrombosis. Integrin α IIb β 3 also participates in cancer progression, such as tumor cell proliferation and metastasis. In resting platelets, integrin α IIb β 3 adopts an inactive conformation. Upon agonist stimulation, the transduction of inside-out signals leads integrin α IIb β 3 to switch from a low- to high-affinity state for fibrinogen and other ligands. Ligand binding causes integrin clustering and subsequently promotes outside-in signaling, which initiates and amplifies a range of cellular events to drive essential platelet functions such as spreading, aggregation, clot retraction, and thrombus consolidation. Regulation of the bidirectional signaling of integrin α IIb β 3 requires the involvement of numerous interacting proteins, which associate with the cytoplasmic tails of α IIb β 3 in particular. Integrin α IIb β 3 and its signaling pathways are considered promising targets for antithrombotic therapy. This review describes the bidirectional signal transduction of integrin α IIb β 3 in platelets, as well as the proteins responsible for its regulation and therapeutic agents that target integrin α IIb β 3 and its signaling pathways.

Keywords: Integrin α IIb β 3, Signal transduction, Talin, Kindlin, Transmembrane proteins, Therapeutic targeting

Background

Integrins, a family of transmembrane glycoprotein signaling receptors, comprise two distinct, noncovalently associated subunits, α and β . Each subunit consists of a large extracellular domain that contributes to ligand binding, a single-pass transmembrane (TM) domain, and a smaller unstructured cytoplasmic tail of approximately 20~70 amino acids (except β 4). The cytoplasmic tail provides binding sites for adaptors, signaling proteins, and cytoskeleton-associated proteins, which play an essential role in integrin bidirectional signaling (inside-out signaling and outside-in signaling) [1]. In

mammals, 18 α and 8 β subunits can combine in a restricted manner to form at least 24 integrins, which exhibit considerably different ligand binding properties, resulting in wide-ranging impacts on cellular functions, such as cell adhesion, spreading, migration, survival, differentiation, proliferation, and apoptosis [1]. Integrins can be grouped into 8 subgroups based on the identity of their β subunits (β 1, β 2, β 3, β 4, β 5, β 6, β 7, and β 8) [1]. Two subgroups of integrins are present in human platelets: β 1 and β 3, which account for a total of five human platelet integrins. Three β 1 integrins are found in platelets, namely, α 2 β 1, α 5 β 1, and α 6 β 1, which support platelet adhesion to the extracellular matrix proteins collagen [2], fibronectin [3], and laminin [4, 5], respectively. Two β 3 integrins are present on platelets, namely, α v β 3 and α IIb β 3 [4, 5]. A variety of cells, including endothelial cells, smooth muscle cells, and fibroblasts, express α v β 3. However, there are only a few hundred copies of integrin α v β 3 per platelet [6, 7], and its function in platelets remains poorly understood. By

* Correspondence: xiaodong@shsmu.edu.cn; jiej0503@zju.edu.cn

[†]Jiansong Huang and Xia Li contributed equally to this work.

⁸State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Collaborative Innovation Center of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

¹Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Full list of author information is available at the end of the article



contrast, α Ib β 3, also known as the glycoprotein GPIIb/IIIa (CD41/CD61) complex, is the dominant integrin on platelets and is essential for normal platelet functions. Integrin α Ib β 3 was also found to be expressed in tumor cells [8]. Integrin α Ib β 3 can bind to several arginine-glycine-aspartic acid (RGD)-containing ligands, including fibrinogen, fibrin, von Willebrand factor (vWF), and fibronectin. Of these ligands, fibrinogen is the major ligand. Integrin α Ib β 3 also interacts with the KQAGDV sequence of the fibrinogen γ -chain to cross-link platelets [9]. Glanzmann's thrombasthenia (GT) is a rare autosomal recessive bleeding disorder that arises from disrupted α Ib and/or β 3 subunit synthesis and function due to missense, nonsense, frame shift, or point mutations and exon skipping in the α Ib or β 3 genes. This disruption impairs normal platelet functions, such as adhesion, spreading, and aggregation [10–12]. However, nonphysiological α Ib β 3-mediated platelet activation and aggregation often cause pathological arterial thrombosis [13].

Quantitative studies using 7E3 mAbs eventually confirmed that each unstimulated platelet presents approximately 50,000–100,000 copies of α Ib β 3 on its surface [14], and additional α Ib β 3 molecules in the α -granule membranes are recruited to the platelet surface during platelet secretion, particularly by stimulatory agonists, such as thrombin or adenosine diphosphate (ADP) [15, 16]. A critical characteristic of α Ib β 3 is that it can transmit bidirectional signaling. In resting platelets, integrin α Ib β 3 adopts an inactive conformation. In this state, the extracellular domain has low affinity for its ligands. However, upon agonist stimulation, the cytoplasmic tails of integrin α Ib β 3 are bound by intracellular proteins, particularly talin and/or kindlin. Binding triggers an unclasp of the intracellular and transmembrane α Ib β 3 complex, leading to a conformational change in the extracellular domain. This conformational change leads α Ib β 3 to switch from low affinity (inactive) to high affinity (active) for its ligand (fibrinogen). This process is known as inside-out signaling or integrin α Ib β 3 activation. The outside-in signaling of α Ib β 3 on platelets is triggered by the binding of fibrinogen to activated integrin α Ib β 3, leading to a cascade of intracellular signaling events that mediate irreversible stable adhesion, spreading, clot retraction, irreversible aggregation, and cytoskeletal reorganization of platelets, as well as subsequent thrombus growth.

Bidirectional signaling of integrin α Ib β 3 is vital for platelet functions, hemostasis, and arterial thrombosis. Bidirectional signaling of integrin α Ib β 3 also plays an important role in cancer progression through regulating the interaction of integrin α Ib β 3 with the fibrinogen/ α v β 3 complex on the surface of tumor cells [8] and/or releasing vascular endothelial growth factor (VEGF) from activated platelets [17]. An improved understanding of

integrin α Ib β 3 signal transduction and regulation will result in greater progress in understanding thrombosis and developing therapeutic agents. Several excellent reviews have provided an overview of the structure of integrin α Ib β 3 and its bidirectional signaling [18–23]. This brief review describes platelet integrin α Ib β 3 bidirectional signaling, the proteins responsible for regulating signal transduction, and the therapeutic agents targeting integrin α Ib β 3 and/or its signaling.

Integrin α Ib β 3 inside-out signaling

The inside-out signaling of α Ib β 3 on platelets can be initiated by various soluble agonists, such as epinephrine, ADP, thromboxane A2 (TXA2), or thrombin, which bind to G protein-coupled seven-transmembrane domain receptors (GPCRs). Inside-out signaling can also be initiated by immobilized agonists, such as vWF or collagen, which mainly interact with GPIb-IX-V or GPVI, respectively. Inside-out signaling includes (1) intracellular activators (such as talin or kindlin) binding to integrin α Ib β 3 tails, (2) separation of the α and β TM and the cytoplasmic tail, (3) a conformational change of the extracellular domain of α Ib β 3, and (4) increasing ligand binding affinity and avidity. To date, talin, kindlin, and other proteins have been identified as directly or indirectly interacting with integrin cytoplasmic tails to participate in the inside-out signaling of α Ib β 3 [24].

Talin

Talin has long been known to play an essential role in integrin activation. As an integrin-actin adaptor protein, it is an autoinhibited dimer with a head-to-tail conformation [25]. It consists of a globular N-terminal head (talin-H, approximately 50 kDa) and a large flexible C-terminal rod region (talin-R, approximately 200 kDa) (Fig. 1) [26]. There is a short linker sequence containing a calpain-II cleavage site between the talin-H and talin-R regions [27]. The talin-H region contains an F0 subdomain and a so-called 4.1, ezrin, radixin, moesin (FERM) domain, comprising three subdomains named F1, F2, and F3. The F3 subdomain has a phosphotyrosine-binding domain (PTB)-like fold [28], which binds with high affinity to the first (or membrane-proximal) of two conserved NPXY motifs in the β tails at integrin-binding site 1 (IBS1) [29]. The F3 subdomain can also interact with phosphatidylinositol 4-phosphate 5-kinase isoform 1 γ (PIP1 γ) [30], layilin [31], and focal adhesion kinase (FAK) [32]. The talin-R region is composed of 13 amphipathic helical bundle domains (R1-R13, containing 62 α -helices), each consisting of four or five α -helices. The talin-R region contains at least two actin-binding sites [33], a second integrin-binding site (IBS2) [34], and multiple binding sites for vinculin [35]. Thus, talin-H binds to the evolutionarily conserved NPXY motif of the β




Fig. 1 Domains and binding sites of talin. Talin-H comprises an atypical FERM domain containing F0, F1, F2, and F3 domains. Talin-R is composed of 13 amphipathic helical bundle domains (R1-R13, containing 62 α -helices), each consisting of four or five α -helices. A calpain-II cleavage site lies between talin-H and talin-R. Binding sites for interacting proteins are indicated by horizontal lines

cytoplasmic tails of integrins, connecting the integrin with the actin cytoskeleton through the actin-binding site of talin-R.

Over the past 20 years, studies in cultured cells [36], mouse models [37, 38], and purified protein-reconstituted systems [39] have reinforced the notion that talin is an essential regulator of integrin ligand affinity. Binding of talin-H to the conserved N⁷⁴⁴PLY⁷⁴⁷ motif of the β 3 tail is proposed to induce α IIB β 3 activation by disrupting the salt bridge between α IIB and the β 3 tail [21]. Talin-H is sufficient to induce integrin activation, as evidenced by the fact that talin-H was able to induce integrin α IIB β 3 binding to the activation-specific mAb PAC-1 [40]. Studies on murine embryonic stem cell-derived megakaryocytes with talin knockdown have shown that talin is required for integrin α IIB β 3 activation in response to different agonists [41]. Furthermore, mice expressing the L⁷⁴⁶A mutation of β 3 integrin, which is believed to selectively disrupt the interaction between α IIB β 3 and talin, display impaired inside-out activation of α IIB β 3 [42]. Conditional deletion of *talin-1* in mice showed that integrin α IIB β 3 is unable to activate in response to any tested agonists [43, 44]. This finding suggests that talin plays a crucial role in homeostasis and that talin is required for the activation and function of α IIB β 3 in vivo [43, 44]. Thus, disruption of the interaction of talin with integrin β 3 may offer a strategy for anti-thrombosis [42, 45]. Recent data utilizing phospholipid nanodiscs bearing a single lipid-embedded integrin have also shown that talin-H binding to the integrin β 3 tail is sufficient for integrin activation in the absence of other proteins [39]. However, solid evidence has clearly demonstrated that integrin activation also requires the cooperation of kindlin alongside talin [46–51].

Kindlin

A series of publications have established a requirement for kindlin coordinating with talin for integrin α IIB β 3

inside-out signaling [47, 48, 52, 53]. In mammals, there are three evolutionarily conserved members of the kindlin family: kindlin-1, kindlin-2, and kindlin-3 [54, 55]. Kindlin-1 is ubiquitously expressed in epithelial cells, and kindlin-2 is broadly expressed in all solid tissues of mesenchymal origin. In contrast, kindlin-3 is mainly restricted to hematopoietic cells [56, 57]. However, recent experimental work has shown that kindlin-3 is also expressed in endothelial cells [58]. Mutations in the *kindlin-1* gene lead to Kindler syndrome, which is characterized by serious skin blistering, progressive poikiloderma, photosensitivity, and atrophy of the skin [59, 60]. Mutations in the *kindlin-3* gene lead to type-III leukocyte adhesion deficiency (LAD-III), as well as recurrent infections, immune deficiencies, and severe bleeding disorders caused by the dysfunction of integrins in leukocytes and platelets; loss of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) in the bone marrow; elevated leukocyte counts; and osteopetrosis [61–64]. To date, no human diseases have been associated with mutations of the *kindlin-2* gene, but kindlin-2 is highly expressed in cancers of the lung, prostate, pancreas, liver, and esophagus [65]. Knockout of *kindlin-2* is embryonically lethal in mice and causes multiple severe abnormalities in zebrafish due to impaired integrin activation [49, 66, 67].

Using Chinese hamster ovary (CHO) cells expressing integrin α IIB β 3, the Calderwood group reported that kindlin-1 and talin cooperatively enhance integrin α IIB β 3 activation [52, 68] and that kindlin-2 is also a coactivator of talin-H in regulating integrin α IIB β 3 activation [48, 49]. Using *kindlin-3*^{-/-} mice, Moser et al. showed that in platelets lacking kindlin-3, integrin α IIB β 3 could not be activated despite normal talin expression [47]. Kindlin itself is incapable of unclasping the intracellular and transmembrane α IIB β 3 complex [69], and consequently, it is insufficient to trigger effective inside-out signaling of integrin α IIB β 3 [48]. However,

there is a lack of evidence for the direct interaction between kindlins and talin-H [69]. Further studies will be required to address the unanswered question of how kindlin cooperates with talin to induce integrin activation. The tyrosine phosphorylation of the membrane-proximal N⁷⁴⁴PLY⁷⁴⁷ motif of the integrin β 3 tail negatively regulates talin binding [70, 71]. Similar to talin, tyrosine phosphorylation of the membrane-distal N⁷⁵⁶ITY⁷⁵⁹ motif also inhibits kindlin-2 binding [46]. These observations suggest that transitions between the phosphorylated and non-phosphorylated states of the integrin β 3 tail affect talin/kindlin-regulated integrin activation [46]. Tyrosine phosphorylation of the β 3 tail also regulates β 3 cleavage by calpain [72]. Structures of the kindlin-2/ β -tail complex showed that the dimeric forms of kindlin-2 can bridge talin-activated integrins and promote integrin clustering [73]. Recent studies revealed that integrin-linked kinase (ILK) can interact with the F2 subdomain of kindlin-2 with high affinity and support α IIB β 3 activation [74, 75]. ADAP, a hematopoietic-specific adapter protein, is physically proximal to talin and kindlin-3 in human platelets. ADAP, when acting as a bridging molecule between kindlin and talin, promotes platelet integrin α IIB β 3 activation [38, 76, 77]. The paxillin (PXN) family members (paxillin and Hic-5) act as bridging molecules and are also able to promote platelet integrin α IIB β 3 activation by cooperating with kindlin and talin [51, 78, 79]. However, the exact details of how ILK, ADAP, paxillin, and Hic-5 assist kindlin and talin in mediating α IIB β 3 activation remain largely unknown.

Other proteins that positively regulate integrin α IIB β 3 activation

In addition to talin and kindlin, other proteins, such as ILK [80], β 3-endonexin [81, 82], calcium- and integrin-binding protein 1 (CIB1) [83, 84], chloride channel regulatory protein (ICln) [85], catalytic subunit of protein phosphatase 1 γ (PP1 γ) [86], and vinculin [87], may be involved in integrin α IIB β 3 activation. However, little is known about how these proteins exert effects on integrin activation and signaling. In addition to interacting with kindlin, ILK serves as an adaptor protein that forms the ILK/PINCH/parvin (IPP) complex with PINCH and parvins. The IPP complex interacts directly with the β 3 cytoplasmic tail via ILK and regulates integrin activation in platelets. Loss of ILK has been reported to inhibit integrin activation, as assessed by the binding of soluble fibrinogen and PAC-1 [75, 80, 88, 89]. Platelets stimulated by ADP or phorbol 12-myristate 13-acetate (PMA) exhibited an increase in ILK activity associated with phosphorylation of β 3 [90]. *ILK*^{-/-} mice showed increased bleeding time, reduced aggregation, soluble fibrinogen binding, and defects in α -granule secretion [88]. These observations suggested that ILK may be

involved in integrin α IIB β 3 inside-out and outside-in signaling. β 3-Endonexin is a molecule that is known to induce α IIB β 3 activation in CHO cells by interacting with the N⁷⁵⁶ITY⁷⁵⁹ motif of the integrin β 3 cytoplasmic tail. β 3-Endonexin is present in resting human platelets. Nonetheless, there is little available information about how β 3-endonexin regulates integrin α IIB β 3 [91, 92]. CIB1 can disrupt the association of α IIB and β 3 by binding to the α IIB cytoplasmic tail, which in turn activates integrin α IIB β 3 [83, 93]. However, CIB1 has also been reported to negatively regulate the activation of integrin α IIB β 3 by competing with talin for binding to α IIB β 3 [84]. ICln binds to the membrane-proximal KVGFFKR motif of integrin α IIB regardless of the integrin activation state, and ICln regulates platelet activation through an integrin activation-dependent subcellular redistribution mechanism [85]. Using the γ isoform of PP1c-deficient (*PP1 γ* ^{-/-}) mice, Gushiken et al. showed that PP1 γ mainly participates in thrombin-induced integrin α IIB β 3 inside-out signaling but not ADP or collagen-related integrin α IIB β 3 inside-out signaling. Vinculin, a marker for integrin-mediated focal adhesion complexes, inhibits Rap1-GTP-interacting adaptor molecule (RIAM) binding to talin and plays a role in inside-out signaling of α IIB β 3 [87, 94]. Using CHO cells expressing α IIB β 3, Ohmori et al. reported that vinculin induces α IIB β 3 inside-out signaling through talin-1, while it is dispensable for outside-in signaling [87]. However, conditional deletion of the vinculin gene (*Vcl*) showed that tail bleeding times in *Vcl*^{-/-} mice were prolonged, but platelet functions, including agonist-induced fibrinogen binding to α IIB β 3, spreading, clot retraction, platelet aggregation, and adhesion on immobilized fibrinogen or collagen, were similar to those of wild-type mice [95].

Proteins that negatively regulate integrin α IIB β 3 activation


Several proteins are thought to bind directly to one of the integrin α IIB or β 3 cytoplasmic tails to inhibit integrin α IIB β 3 activation. CIB1 plays a role in the possible negative regulation of integrin α IIB β 3 activation by binding directly to the GFFKR sequence of the α IIB cytoplasmic tail [84, 96], whereas docking protein 1 (Dok1) [71], filamin [97], and tensin 1 [98] impair integrin activation by binding directly to the β 3 cytoplasmic tail [99]. There are conflicting reports on the function of CIB1 proteins in α IIB β 3 activation. Tsuboi et al. first reported that CIB1 plays an important role in the activation of α IIB β 3 in platelets [83]. When platelets were incubated with a palmitoylated peptide corresponding to the C-terminus of CIB1 (residues 179–188), no significant PAC-1 binding to α IIB β 3 was detected in the presence of physiological agonists such as ADP and thrombin. Contrasting results were reported for the

overexpression of CIB1 in megakaryocytes, which completely prevented agonist-induced integrin α IIB β 3 activation, whereas overexpression of a CIB1 F173A mutant resulted in failure to interact with the α IIB cytoplasmic tail and was unable to suppress agonist-induced integrin α IIB β 3 activation. Conversely, the reduction of endogenous CIB1 via RNA interference enhanced agonist-induced integrin α IIB β 3 activation [84]. However, Denofrio et al. reported that there was no significant difference in integrin α IIB β 3 expression, agonist-induced α IIB β 3 binding to JON/A, P-selectin expression, platelet aggregation, platelet spreading, bleeding time, or FeCl₃-induced thrombus formation between *Cib1*^{+/+} and *Cib1*^{-/-} mice, possibly owing to compensation by CIB2 and CIB3 [100]. In contrast to the report of Denofrio et al., *Cib1*^{-/-} mice showed a rebleeding phenotype and defective thrombosis due to impaired integrin α IIB β 3 outside-in signaling [101]. Dok1 is a PTB domain-containing protein. Expression of Dok1 in CHO cells expressing chimeric α IIB β 6A β 3 β 1A inhibited integrin activation by competing with talin for the PTB binding sites in the β 1A cytoplasmic tail [102]. The integrin β 3 cytoplasmic tail also has the ability to bind Dok1 [103] and impair α IIB β 3 activation. Recent studies revealed that the 14-3-3 ξ /Dok1 binary complex binds to the phosphorylated cytoplasmic tail of integrin β 3 and regulates integrin activation [104]. Some studies reported that knockout of Dok1 or Dok2 did not affect platelet integrin α IIB β 3 inside-out signaling, as evidenced by normal aggregation, JON/A binding, and soluble fibrinogen [105, 106]. Crystal structure studies have shown that filamin and tensin 1 can compete with talin for binding to the integrin β 3 tail [107]. The roles of filamin and tensin 1 in α IIB β 3 inside-out signaling need to be further investigated using CHO cells or platelets. A gain-of-function mutation in filamin A (stop codon mutation *p. Ter2648SerextTer101*) potentiates platelet integrin α IIB β 3 activation by facilitating recruitment of talin to the β 3 tail [108]. Recent studies have demonstrated that α -actinin plays a role in maintaining α IIB β 3 in an inactivated state [109]. Due to partial overlapping of α -actinin binding sites with talin binding sites in the β 3 cytoplasmic tail, α -actinin association with α IIB β 3 may block the access of talin to the β 3 tails [109, 110]. α -Actinin induces a kink in the transmembrane domain of integrin β 3 [109–111], which maintains integrin α IIB β 3 in a low-affinity state [111].

Agonist-induced integrin α IIB β 3 activation

Knowledge of how agonists lead to integrin α IIB β 3 activation by talin and/or kindlin is vital for understanding inside-out signaling of α IIB β 3 (Fig. 2). The initial adhesion of platelets at the site of damaged vessel walls is mainly facilitated by GPIb-IX-V/collagen-bound vWF and/or GPVI-collagen interactions. These two interactions trigger

integrin α IIB β 3 inside-out signaling and play a primary role in platelet activation. The GPIb-IX-V complex contains four type I transmembrane glycoproteins: GPIb α , GPIb β , GPIX, and GPV. After vascular injury, circulating vWF in the plasma binds to the exposed collagen within the subendothelium through its A3 domain. The interaction of collagen and vWF-A3 enables vWF to expose the A1 domain, which is essential for collagen-bound vWF to interact with the GPIb subunit. In addition, factor XII, P-selectin, and leukocyte integrin MAC-1 are all able to bind to GPIb-IX-V and modulate integrin α IIB β 3 activation [112]. The interaction of vWF with GPIb-IX-V induces activation of the Src family kinases (Src, Lyn, and Fyn) and phosphorylation of its downstream substrates, including the Fc receptor γ -chain (FcR γ) and FcR γ Ia [113–116]. PLC γ tyrosine phosphorylation is mediated by the immunoreceptor tyrosine-based activation motif (ITAM)-bearing receptors FcR γ and FcR γ Ia. PLC γ is also activated by GPVI-collagen interactions through FcR γ signaling involving tyrosine kinases, such as Src and spleen tyrosine kinase (Syk) [117]. In addition to PLC γ , phosphatidylinositol-3-kinase (PI3K) is another key molecule downstream of GPVI and GPIb-IX-V [118]. Collagen- or vWF-induced signaling leads to the release of ADP, TXA₂, 5-hydroxytryptamine (5-HT), and thrombin, which triggers PLC β activation via GPCRs, such as the P2Y₁, TP, 5-HT_{2A}, and PAR receptors. PLC β is downstream of GPCRs, whereas PLC γ is activated by vWF/GPIb-IX-V or collagen/GPVI interactions [118, 119]. PI3K signaling leads to Rap1 activation, which is a Ca²⁺-independent process [120]. Unlike PI3K, PLC activation hydrolyzes platelet membrane phosphatidylinositol (4,5)-bisphosphate (PI-4,5-P) into the second messengers diacylglycerol (DAG) and inositol (1,4,5)-triphosphate (IP₃). In turn, IP₃ releases calcium from intracellular stores through IP₃ receptor (IP₃-R) channels [121], increasing the Ca²⁺ concentration in the platelet cytosol. DAG and Ca²⁺ activate many isoforms of platelet protein kinase C (PKC) and Ca²⁺ diacylglycerol guanine-nucleotide-exchange factor I (CalDAG-GEFI, a guanine exchange factor for Rap1), leading to the conversion of Rap1-GDP to Rap1-GTP and the translocation of Rap1-GTP to the plasma membrane [122–124]. In *CalDAG-GEFI*^{-/-} mice, induction of inside-out activation of integrin α IIB β 3 by calcium ionophore, collagen, ADP, and a TXA₂ analog was strongly inhibited. In contrast, thrombin-induced activation of α IIB β 3 was mildly affected [125]. This finding suggests that other molecules may transform the signal from the agonist to the α IIB β 3 cytoplasmic tails and cause α IIB β 3 activation. In addition to CalDAG-GEFI, the activation of PKC also leads to the shift of Rap1-GDP to Rap1-GTP in platelets. There are at least four PKC isoforms (α , β , δ , and θ) [126] in human platelets. Using CHO cell models, Han et al. reported that



Rap1-GTP was downstream of $\text{PKC}\alpha$ in integrin $\alpha\text{IIb}\beta_3$ activation [127]. Platelets from $\text{PKC}\alpha^{-/-}$ mice showed that $\text{PKC}\alpha$ was a regulator of inside-out signaling of $\alpha\text{IIb}\beta_3$ [128] but did not play a significant role in the outside-in signaling of $\alpha\text{IIb}\beta_3$. $\text{Rap1b}^{-/-}$ mice demonstrated that ADP- or AYPGKF-induced integrin $\alpha\text{IIb}\beta_3$ activation was impaired, as was FeCl_3 -dependent arterial thrombosis [129]. Interestingly, overexpression of Rap1a in CHO cells leads to $\alpha\text{IIb}\beta_3$ activation [127], but it does not appear to be required for integrin $\alpha\text{IIb}\beta_3$ activation in platelets [129].

Rap1 mediates inside-out activation of integrin $\alpha\text{IIb}\beta_3$ through another effector, called Rap1-GTP-interacting adaptor molecule (RIAM), on the membrane. RIAM is a member of the Mig-10/RIAM/lamellipodin (MRL) family of adaptor molecules. RIAM recruits talin-1 to integrin $\alpha\text{IIb}\beta_3$. Knockout of RIAM in megakaryocytes abolishes Rap1-dependent $\alpha\text{IIb}\beta_3$ activation [130]; however, deletion of RIAM in mice does not affect $\alpha\text{IIb}\beta_3$ activation [131]. Rap1 activation induces the formation

of an “integrin activation complex” containing Rap1, RIAM, and talin, leading to $\alpha\text{IIb}\beta_3$ activation [127, 130]. Bimolecular fluorescence complementation (BiFC) has revealed that in CHO cells, knockdown of RIAM blocks talin recruitment to $\alpha\text{IIb}\beta_3$, whereas overexpression of Rap1a or RIAM enhances talin recruitment to $\alpha\text{IIb}\beta_3$ [132]. RIAM acts as a scaffold that connects the membrane targeting sequences in Rap1-GTP to talin, thereby recruiting talin to the plasma membrane and activating integrins [130]. Whether kindlin is a member of the “integrin activation complex” still warrants further investigation. In addition to the Rap1/RIAM/talin complex pathway, membrane-anchored Rap1b interacts with the F0 domain of talin, triggering integrin $\alpha\text{IIb}\beta_3$ activation in a RIAM-independent fashion [133]; however, a recent study reported conflicting results [134]. The interaction of the F0 domain of talin with Rap1b plays no evident role in talin-H-induced $\alpha\text{IIb}\beta_3$ activation [134]. Schiemer et al. recently reported that switch region 2 of G13 α had the ability to mediate talin activation from

its autoinhibition station and further regulate integrin α IIB β 3 activation [135].

Integrin α IIB β 3 outside-in signaling

The outside-in signaling of integrin α IIB β 3 on platelets is triggered by the binding of soluble fibrinogen to activated integrin α IIB β 3 (Fig. 3), leading to the generation of a cascade of intracellular signaling events that mediate irreversible stable adhesion, spreading, cytoskeletal reorganization and irreversible aggregation of platelets, and subsequent thrombus growth. Similar to the inside-out signaling of α IIB β 3, outside-in signaling of α IIB β 3 requires cooperating proteins to directly or indirectly interact with the α IIB β 3 cytoplasmic tails because the cytoplasmic tails themselves lack any intrinsic enzymatic activity (Fig. 4). Many of the recent advances in our understanding of the proteins that regulate outside-in signaling of α IIB β 3 have come from mouse gene knock-out studies (Table 1). To date, the identified proteins that participate in outside-in signaling of α IIB β 3 are more numerous than those involved in inside-out signaling of α IIB β 3. However, there are some proteins associated with both inside-out and outside-in signaling, such as talin and kindlin-3. The proteins that regulate

outside-in signaling of α IIB β 3 can be classified into four major categories: transmembrane proteins, intracellular adaptor molecules, kinases and phosphatases, and Rho-family small GTPases.

Transmembrane proteins

Immunoglobulin superfamily

Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is a membrane-spanning immunoglobulin protein that regulates outside-in signaling, but not inside-out signaling, of integrin α IIB β 3 [136, 137]. PECAM-1 recruits SHP-1 and SHP-2 to form a signaling complex, leading to Src and FAK activation. However, exactly how Src and FAK are activated following SHP-1 and SHP-2 recruitment to PECAM-1 are unknown. PECAM-1 can also trigger the internalization of GPIIb [138]. Recently, G6B and carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM-1), which bears some similarities to PECAM-1 in its cytoplasmic tail, which contains ITIM domains, and its capacity to recruit SHP-1 and SHP-2, have been shown to negatively regulate platelet thrombus formation in vitro and in vivo [137, 139–142]. Interestingly, platelets also express junctional adhesion molecule-A (JAM-A) [143] and endothelial cell-specific




Fig. 3 Schematic of integrin α IIB β 3 outside-in signaling in platelets. Following ligand binding to the extracellular domain of integrin α IIB β 3, integrin α IIB β 3 clustering promotes Src activation by autophosphorylation. Calpain cleaves the integrin β 3 cytoplasmic tail and leads to disassociation of partly active Src from the integrin β 3 tail. Src phosphorylates and supports the activation of a wide range of enzymes and signaling proteins, such as FAK, Syk kinase, RhoGAP, Rac-GEFs, RhoGEFs, and PI3K. G α 13, talin, kindlin, tensin, and vinculin provide the necessary links between the integrin β 3 cytoplasmic tail and actin. Kindlin can directly couple integrin β 3 to the actin cytoskeleton via the ILK/PINCH/parvin complex




Fig. 4 Amino acid sequence of the C-terminal tail of integrin $\beta 3$, highlighting interaction sites involved in integrin $\alpha \text{IIb}\beta 3$ bidirectional signaling. Calpain cleavage sites are indicated by arrows. Phosphorylatable amino acid residues (tyrosine and threonine) are labeled in red. Positions of the horizontal lines indicate sites on the integrin $\beta 3$ cytoplasmic tail that interact with cytoplasmic signaling proteins

adhesion molecule (ESAM) [144, 145], which belongs to the cortical thymocyte marker of *Xenopus* (CTX) family of the immunoglobulin superfamily. JAM-A likely indirectly associates with integrin $\alpha \text{IIb}\beta 3$ through CD9 [146]. In mouse knockout models, JAM-A was reported to negatively regulate $\alpha \text{IIb}\beta 3$ outside-in signaling-mediated platelet thrombus formation through binding to Syk and inhibiting the activation of $\alpha \text{IIb}\beta 3$ -associated Src [147, 148].

Tetraspanin superfamily

The tetraspanins possess four conserved hydrophobic transmembrane regions: two extracellular loops and two intracellular tails (N-terminal and C-terminal). At least five members of the tetraspanin superfamily, CD151, tumor suppressing subtransferable candidate 6 (TSSC6), CD63, CD9, and CD82, have been reported to be expressed in platelets [149–153]. However, there is little information on how these tetraspanins influence $\alpha \text{IIb}\beta 3$ outside-in signaling. So far, immunoprecipitation and Western blot studies have revealed the physical association of CD151, CD63, TSSC6, and CD9 with $\alpha \text{IIb}\beta 3$ in platelets [150, 151, 154, 155].

Studies using murine *CD151*^{-/-} platelets have demonstrated that deletion of CD151 is capable of inhibiting the outside-in signaling properties of $\alpha \text{IIb}\beta 3$, including reducing agonist-induced platelet aggregation, delaying clot retraction, diminishing platelet spreading on fibrinogen, and reducing formation of filopodia. However, *CD151*^{-/-} platelets display normal $\alpha \text{IIb}\beta 3$ inside-out signaling properties, as evidenced by standard agonist-induced binding of soluble fibrinogen or JON/A antibody [150, 156, 157]. Recent studies by Orłowski et al. that used three different models for thrombus formation have confirmed that platelet CD151 is required for regulating thrombus formation in vivo [149]. CD151 forms a CD151/P2Y₁₂ receptor complex and participates in

integrin $\alpha \text{IIb}\beta 3$ outside-in signaling [157]. TSSC6 regulates integrin $\alpha \text{IIb}\beta 3$ outside-in signaling by physically associating with the P2Y₁₂ receptor [158]. Early studies suggested that CD63 might inhibit integrin $\alpha \text{IIb}\beta 3$ outside-in signaling in platelets. D545, a CD63 monoclonal antibody, modulates $\alpha \text{IIb}\beta 3$ -mediated actin cytoskeleton reorganization, inhibiting platelet spreading on immobilized fibrinogen and impairing tyrosine phosphorylation of FAK. Tyrosine phosphorylation of FAK is a downstream marker of integrin $\alpha \text{IIb}\beta 3$ outside-in signaling. Unlike the CD151 and TSSC6 tetraspanins, CD9 does not appear to play an important role in integrin $\alpha \text{IIb}\beta 3$ outside-in signaling but does negatively regulate integrin inside-out signaling [159]. Future studies are required to explore the role of the tetraspanins in $\alpha \text{IIb}\beta 3$ signaling.

Other transmembrane proteins

Growth arrest-specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. Recent studies of *Gas6*^{-/-} mice have shown that Gas6 plays a role in platelet function [160–162]. *Gas6*^{-/-} mice have a normal bleeding time but a tendency to repetitively rebleed due to impaired $\alpha \text{IIb}\beta 3$ outside-in signaling [160]. Interestingly, mice that have lost any one gene for the TAM family receptors (Tyr_o3, Axl, or Mer) display a phenotype similar to that of *Gas6*^{-/-} mice [163]. Once Gas6 is secreted, it binds to the TAM family receptor on the platelet surface through the C-terminal sex hormone binding globulin (SHBG)-like domain and subsequently activates downstream signaling molecules, including PI3K, Rap1, and Akt. PI3K/Akt activation leads to propagation of $\alpha \text{IIb}\beta 3$ outside-in signaling [164]. There are some transmembrane proteins, such as Semaphorin 4D [165] and the signaling lymphocyte activation

Table 1 Key regulatory proteins involved in integrin $\alpha\text{IIb}\beta\text{3}$ bidirectional signaling

Proteins	Integrin $\alpha\text{IIb}\beta\text{3}$ activation	Phenotype of knockout mice	Reference
ADAP	Significantly reduced soluble fibrinogen binding	Formation of unstable thrombi, increased tail rebleeding, reduced stable attachment, and impaired cytoskeletal reorganization under shear flow	[76, 77]
CalDAG-GEFI	Impaired JON/A antibody binding	Reduced aggregation, granule secretion, and adhesive function. Mild defect in hemostasis. Impaired Rap1 activation	[104, 123–125]
c-Cbl	Null	Significantly reduced spreading on immobilized fibrinogen. Drastically impaired clot retraction	[220]
CD9	Increased soluble fibrinogen binding	Normal aggregation and α -granule release, normal hemostasis	[159]
CD63	Normal JON/A antibody binding	Normal α -granule release. Normal adhesion and thrombus formation on collagen under flow conditions	[249]
CD82	Normal JON/A antibody binding	Normal aggregation and granule secretion. Enhanced clot retraction, enhanced adhesion on fibrinogen. Reduced bleeding time and volume. Increased tyrosine phosphorylation in integrin $\alpha\text{IIb}\beta\text{3}$ signaling	[153]
CD84	Normal JON/A antibody binding	Normal granule secretion. Unaltered hemostatic function and arterial thrombus formation. Unaltered aggregate formation under flow. Unaltered function of $CD84^{-/-}$ platelets in vitro	[167]
CD148	Markedly reduced JON/A antibody binding	Exhibited a bleeding tendency and defective arterial thrombosis. Markedly reduced SFK activity. Impaired spreading on fibrinogen and collagen-induced aggregate formation under flow conditions. Delayed thrombus formation	[250]
CD151	Normal soluble fibrinogen and JON/A antibody binding	Normal α -granule, dense granule secretion, and platelet adhesion. Impaired platelet aggregation and platelet spreading on fibrinogen, delayed kinetics of clot retraction, restricted cytoskeletal reorganization. Increased bleeding time and volume and rebleeding, but without spontaneous bleeding complications	[150, 156, 157]
CEACAM-1	Null	Enhanced aggregation, enhanced platelet adhesion on type I collagen but not fibrinogen, elevated granule secretion, larger and more stable thrombi	[137]
CIB1	Normal soluble fibrinogen binding	Normal aggregation and α -granule secretion, increased tail bleeding time and rebleeding, formation of unstable thrombi, impaired spreading on immobilized fibrinogen, reduced tyrosine phosphorylation of the integrin β3 tail	[93, 101]
cPLA2 α	Impaired fibrinogen binding in response to CRP or the lower concentration of PAR4 peptide	Impaired collagen-induced aggregation, spreading on fibrinogen, platelet aggregation. Prolonged bleeding time	[224, 225]
Dab2	Impaired soluble fibrinogen binding	Selectively defective in thrombin-induced aggregation, platelet spreading on fibrinogen and clot retraction. Impaired ADP release. Prolonged bleeding time and impaired hemostasis and thrombosis	[179]
Dok1	Normal soluble fibrinogen and JON/A antibody binding	Normal aggregation, P-selectin surface expression. Increased clot retraction, increased PLC γ2 phosphorylation, and enhanced spreading on fibrinogen. Significantly shortened bleeding time and accelerated carotid artery thrombosis	[105]
Dok2	Normal soluble fibrinogen and JON/A antibody binding	Enhanced shear-dependent integrin adhesion in platelets. Increased platelet thrombus formation	[106]
ERp57	Impaired JON/A antibody binding	Prolonged tail bleeding time and thrombus occlusion time. Impaired platelet aggregation	[251]
ESAM	Normal JON/A antibody binding	Normal calcium mobilization, α -granule secretion and platelet spreading, more stable hemostasis. Formation of larger thrombi, increased aggregation, and more resistant to disaggregation	[145]
G6b-B	Reduced soluble fibrinogen binding	Megakaryocytes exhibited a marked reduction in spreading on fibrinogen or fibronectin, increased bleeding, failure to form normal aggregates on collagen-coated surfaces under flow condition. Impaired secretion of ATP, but not P-selectin, and reduced spreading	[140, 141]
Ga13	Normal soluble fibrinogen binding	Mutation of the Ga13-binding β3 ExE motif. Impaired stable thrombus formation. Increased tail bleeding time	[168, 169, 181]
Gas6, Gas6 receptors	Normal soluble fibrinogen	Failure to spread to fibrinogen, impaired dense granule secretion. No spontaneous bleeding, normal bleeding time but a tendency to repetitively rebleed. Lacked the second wave of platelet	[160, 161, 163]

Table 1 Key regulatory proteins involved in integrin $\alpha\text{IIb}\beta\text{3}$ bidirectional signaling (*Continued*)

Proteins	Integrin $\alpha\text{IIb}\beta\text{3}$ activation	Phenotype of knockout mice	Reference
	binding, impaired PAC-1 binding	aggregation, with impaired clot retraction, reduced thrombus formation, and increased disaggregation. Reduced tyrosine phosphorylation of the integrin β3 tail	
ILK	Reduced rate of soluble fibrinogen binding	Reduced α -granule secretion. Impaired aggregation, increased thrombus instability and tail bleeding time and volume	[88, 89]
JAM-A	Normal soluble fibrinogen and JON/A antibody binding	Normal α -granule secretion, enhanced thrombus formation, augmented platelet spreading and aggregation, enhanced clot retraction, shortened tail bleeding time	[147, 148]
Kindlin-3	Failed to bind soluble fibrinogen and JON/A antibody	Kindlin-3 deficiency results in severe bleeding and resistance to arterial thrombosis	[47]
Lnk	Normal soluble fibrinogen binding	Normal P-selectin expression. Reduced spreading on fibrinogen, impaired clot retraction, reduced tyrosine phosphorylation of integrin β3 tail. Impaired thrombus stability. Lnk promotes integrin $\alpha\text{IIb}\beta\text{3}$ -mediated actin cytoskeleton reorganization	[176]
MEKK3	Impaired soluble fibrinogen binding	Reduced aggregation and granule secretion. Delayed thrombus formation and fewer microthrombi, normal tail bleeding time	[252]
Myosin	Normal soluble fibrinogen and JON/A antibody binding	Normal platelet aggregation and secretion. Increased bleeding time and absence of clot retraction. Reduced tyrosine phosphorylation of integrin β3 tail. Impaired thrombus growth, organization, and thrombus stability. Increased tail bleeding time	[172]
NLRP3	Normal JON/A antibody binding	Prolonged tail bleeding time, delayed arterial thrombus formation, impaired spreading on immobilized fibrinogen, defective clot retraction, mildly reduced platelet aggregation, normal P-selectin expression, decreased phosphorylation of Src, Syk, and PLC γ2 in response to thrombin stimulation	[13]
Palladin ^{+/-}	Null	Accelerated hemostasis and arterial thrombosis. Increased aggregation, spreading on immobilized fibrinogen, and rate of clot retraction	[253]
Paxillin	Enhanced JON/A antibody binding	Enhanced platelet aggregation and granule secretion, increased spreading on fibrinogen and clot retraction, increased tyrosine phosphorylation and calcium mobilization, increased thrombus formation	[79]
PDK1	Normal soluble fibrinogen binding	Diminished aggregation and spreading on immobilized fibrinogen and decreased rate of clot retraction	[254]
PECAM-1	Normal soluble fibrinogen and JON/A antibody binding	Normal α -granule secretion and aggregation, impaired spreading on immobilized fibrinogen and clot retraction, reduced tyrosine phosphorylation of FAK	[136]
PI3Ka	Null	Impaired platelet aggregation at low concentrations of CRP. Modest but significant decrease in thrombus size after superficial injury of mouse mesenteric arteries. Increased time to arterial occlusion after carotid lesion, without modification of the tail bleeding time	[219]
PKCa	Impaired soluble fibrinogen binding	Normal spreading on fibrinogen and collagen. Impaired granule release and aggregation. Markedly attenuated thrombus formation. Normal tail bleeding time	[128]
PKC β	Normal soluble fibrinogen binding	Spread poorly on fibrinogen	[209]
PKC θ	Increased JON/A antibody binding	Partially impaired spreading on fibrinogen, but not on CRP or collagen. Increased CRP-induced granule release, unaltered platelet aggregation, and formation of significantly larger thrombi	[212, 213]
PKC ζ/λ	Normal JON/A antibody binding	Unaltered platelet spreading and function in vitro and in vivo under all tested conditions. Unaltered in vivo thrombus formation in PKC ζ/λ ^{-/-} mice	[206]
PP1 γ	Moderately decreased soluble fibrinogen	Mild agonist-specific decreased aggregation. Normal granule secretion, adhesion to immobilized fibrinogen, and clot retraction. Significantly delayed thrombus formation	[86]

Table 1 Key regulatory proteins involved in integrin $\alpha\text{IIb}\beta\text{3}$ bidirectional signaling (*Continued*)

Proteins	Integrin $\alpha\text{IIb}\beta\text{3}$ activation	Phenotype of knockout mice	Reference
	binding with low concentrations of thrombin or PAR4, but not ADP, collagen or CRP		
PTEN	Null	Shortened tail bleeding time, increased sensitivity of platelets to collagen-induced activation and aggregation	[255]
PTP-1B	Normal soluble fibrinogen binding	Poor spreading on fibrinogen and decreased clot retraction, markedly reduced thrombus formation. Prolonged tail bleeding time, but without spontaneous bleeding	[199]
Pyk2	Impaired soluble fibrinogen binding	Defective spreading on fibrinogen. Impaired aggregation and thrombus formation. Slightly prolonged tail bleeding	[221, 222]
Rac1	Null	Defective spreading on fibrinogen. Reduced thrombus formation and stability. Prolonged tail bleeding	[228, 256]
<i>Rap1b</i>	Impaired soluble fibrinogen binding	Impaired spreading on fibrinogen. Increased tail bleeding time. Reduced platelet aggregation. <i>Rap1b</i> ^{-/-} mice are protected from thrombosis in an in vivo thrombosis model	[129]
Reelin	Reduced soluble fibrinogen binding	Impaired platelet adhesion. Significantly reduced thrombus formation under high shear conditions and protected from arterial thrombosis. Normal hemostasis	[192]
RhoA	Normal JON/A antibody binding	Impaired α -granule release. Markedly prolonged tail bleeding time but also significant protection in different models of arterial thrombosis and in a model of ischemic stroke. Normal spreading on fibrinogen, impaired clot retraction, moderately reduced aggregate formation	[227]
RIAM	Normal soluble fibrinogen and JON/A antibody binding	Normal adhesion and aggregation responses under static and flow conditions. Unaltered hemostasis and arterial thrombus formation	[131]
ROCK2	Slightly impaired fibrinogen binding	Impaired adhesion and spreading on collagen, reduced aggregation. Prolonged bleeding time and delayed vascular occlusion following vessel injury	[257]
Semaphorin 4D	Normal soluble fibrinogen binding	A selective defect in collagen-induced platelet aggregation and an impaired vascular injury response. Spleen tyrosine kinase activation, and subsequent downstream events are greatly reduced in <i>Sema 4D</i> ^{-/-} platelets. Normal spreading on collagen under flow conditions	[165]
SFKs	Normal JON/A antibody binding	Mouse platelets deficient in c-Src display impaired spreading on fibrinogen. Some redundancy with other SFKs such as Fyn and Lyn occurs, whereas Lyn is important for thrombus formation. However, Lyn also plays a negative regulatory role in cell spreading. <i>Fyn</i> ^{-/-} platelets display delayed spreading on fibrinogen and prolonged rebleeding time. Loss of SFKs does not affect tail bleeding	[114–116, 176, 200, 214]
SHIP1	Null	SHIP1 plays a major role in regulating integrin $\alpha\text{IIb}\beta\text{3}$ -dependent PI(3,4,5)P3 accumulation. Enhanced platelet spreading	[214]
SLP-76	Normal soluble fibrinogen binding	Impaired spreading on fibrinogen, collagen-induced platelet aggregation, and granule release. Fetal hemorrhage. Reduced tyrosine phosphorylation	[171, 182, 183]
Talin	Significantly reduced soluble fibrinogen binding	Impaired integrin $\alpha\text{IIb}\beta\text{3}$ -mediated platelet aggregation and adhesion to collagen. Spontaneous hemorrhage and pathological bleeding	[41, 124]
TSSC6	Normal soluble fibrinogen and JON/A antibody binding	Normal platelet adhesion on fibrinogen and α -granule secretion. Increased bleeding time and volume and rebleeding. Unstable hemostasis. Impaired clot retraction, platelet aggregation, and spreading on fibrinogen	[151]
Vav1/3	Null	Impaired spreading on fibrinogen, reduced $\alpha\text{IIb}\beta\text{3}$ -mediated PLC γ 2 tyrosine phosphorylation, and reduced Ca ²⁺ mobilization	[202]
Vinculin	Normal agonist-induced fibrinogen binding	Normal aggregation, adherence/spreading on immobilized fibrinogen or collagen, actin polymerization/organization, clot retraction. Prolonged tail bleeding time, but no spontaneous bleeding	[95]

Table 1 Key regulatory proteins involved in integrin α Ib β 3 bidirectional signaling (*Continued*)

Proteins	Integrin α Ib β 3 activation	Phenotype of knockout mice	Reference
VPS33B	Normal thrombin-induced soluble fibrinogen and JON/A antibody binding	Impaired spreading on fibrinogen, failure to support clot retraction. Reduced platelet aggregation and ATP secretion. Prolonged tail bleeding time	[170]
WASP	Normal fibrinogen, JON/A antibody and PAC-1 binding	Impaired adherence/spreading on immobilized fibrinogen, clot retraction and postaggregation. Primary hemostasis is normal, but rebleeding is increased	[180]

molecule (SLAM) [166, 167], that regulate integrin α Ib β 3 outside-in signaling in platelets.

Intracellular adaptor molecules

Some intracellular adaptor molecules, such as the heterotrimeric guanine nucleotide-binding protein (G protein) $G\alpha_{13}$ [168, 169], vacuolar protein sorting-associated protein 33B (VPS33B) [170], the SH2 domain-containing leukocyte protein of 76 kDa (SLP-76) [171], myosin [172], Src homology 2 domain-containing transforming protein (Shc) [173], Grb2 [174], Fc γ RIIa [175], lymphocyte adaptor protein (Lnk) [176], stress-activated protein kinase-interacting protein (Sin1) [177], Disabled-2 (Dab2) [178, 179], NLRP3 [13], and Wiskott-Aldrich syndrome protein (WASP) [180], are believed to be involved in integrin α Ib β 3 outside-in signaling. $G\alpha_{13}$ directly binds to the integrin β 3 cytoplasmic tail [168]. The spreading of CHO cells expressing α Ib β 3 on immobilized fibrinogen is inhibited by $G\alpha_{13}$ siRNA interference. Gong et al. reported that platelets transfected with $G\alpha_{13}$ siRNA spread poorly on immobilized fibrinogen and fail to activate Src. The myr-FEEERA peptide disrupted the $G\alpha_{13}/\beta$ 3 interaction, thereby hampering Src activation and ultimately inhibiting α Ib β 3 outside-in signaling [181]. VPS33B, a member of the Sec1/Munc18 family, binds directly to integrin β 3. Overexpression of VPS33B in CHO cells potentiated α Ib β 3 outside-in signaling but not inside-out signaling [170]. VPS33B was recently shown to function upstream of the RhoA-ROCK-MLC and Rac1-dependent pathways that lead to clot retraction and cell spreading [170]. *SLP-76*^{-/-} murine platelets have normal fibrinogen binding but poor spreading. In the absence of SLP-76, collagen-induced platelet aggregation and granule release, as well as the phosphorylation of the β 3 tail, are markedly impaired [182, 183]. Myosin is known to be able to bind to the NPXY motif within β integrin cytoplasmic domains [184]. Outside-in signaling events, such as integrin β 3 phosphorylation, PI-4,5-P accumulation following stimulation, and FeCl₃-induced thrombus formation, are strongly impaired in myosin-deficient mice [172]. Fibrinogen binding to

platelet α Ib β 3 induces integrin cytoplasmic domain-dependent phosphorylation of Fc γ RIIa, which plays an important role in α Ib β 3-mediated outside-in signaling [175]. Platelets from *Lnk*^{-/-} mice exhibit reduced abilities in terms of full spreading on fibrinogen, fibrin clot retraction, platelet aggregation, and stable thrombus formation. Lnk is thought to mediate α Ib β 3-dependent outside-in signaling through facilitating Src phosphorylation of Fyn [176]. Shc and Grb2 are known adaptor proteins that associate with the phosphorylated β 3 tails involved in outside-in signaling [173]. Disabled-2 (Dab2) is known to be expressed in megakaryocytes and platelets. Dab2 has two isoforms: p82 and p59. Ser24 of Dab2 is phosphorylated by PKC β II, PKC γ , and PKC δ , which interact with integrin β 3 and ultimately inhibit integrin α Ib β 3 activation [178]. The balance between the two isoforms of Dab2 controls integrin α Ib β 3 outside-in signaling [178]. NLRP3 regulates platelet integrin α Ib β 3 outside-in signaling by decreasing thrombin-induced phosphorylation of Src/Syk/PLC γ 2 [13]. Data from *WASP*^{-/-} mice showed that integrin α Ib β 3 outside-in signaling, such as fibrinogen and JON/A binding under agonist stimulation, is normal, whereas integrin α Ib β 3 outside-in signaling-dependent events, such as spreading on immobilized fibrinogen, fibrin clot retraction, and rebleeding, are impaired [180]. Some extracellular materials, pathogens, and other factors, such as amyloid- β [185], UV [186], *Mucor circinelloides* [187], heparin [188], and hypoxia [189], also regulate α Ib β 3 signaling. Peroxisome proliferator-activated receptor γ (PPAR γ) [190], reelin [191, 192], and disulfide isomerase [193] were also reported to be involved in integrin α Ib β 3 outside-in signaling.

Kinases, phosphatases, and Rho-family small GTPases

The maintenance of normal platelet integrin α Ib β 3 signal transduction depends on numerous kinases and phosphatases that participate in the cascade of phosphorylation and dephosphorylation. To date, more than 10 enzymes have been reported to be involved in integrin α Ib β 3 outside-in signaling. The earliest phosphorylation event after fibrinogen binding to α Ib β 3 is

the activation of Src kinase. Src has been reported to directly and constitutively associate with arginine-glycine-threonine (RGT) residues of the integrin $\beta 3$ cytoplasmic tail via its SH3 domain [194, 195]. In resting platelets, integrin $\alpha \text{IIb}\beta 3$ -associated Src may not be activated because tyr418 of the Src activation loop is not phosphorylated and because its SH2 domain binds to phospho-tyr529. Phosphorylation of tyr529 is maintained by C-terminal Src kinase (Csk). Interestingly, RGT-containing peptides have the ability to abrogate the interaction of Src with $\beta 3$ and thus selectively inhibit integrin $\alpha \text{IIb}\beta 3$ outside-in signaling in platelets [196, 197]. Furthermore, experimental data from the $\beta 3$ ($\Delta 760$ -762) knockin mouse has demonstrated that deletion of RGT residues of $\beta 3$ disrupts Src-mediated $\alpha \text{IIb}\beta 3$ signaling [198].

Following platelet activation by agonists, fibrinogen binds to $\alpha \text{IIb}\beta 3$ and then results in tyr529 of Src being dephosphorylated by protein-tyrosine phosphatase-1B (PTP-1B) [199]. After Src activation, Syk is recruited to the $\beta 3$ tail and activated by Src [200]. Some adaptor molecules, such as SLP-76, Vav1, Vav2, Val3, and SLAP-130, are downstream of Syk in $\alpha \text{IIb}\beta 3$ outside-in signaling [171, 201, 202]. There are some controversies concerning the role of Syk in $\alpha \text{IIb}\beta 3$ outside-in signaling. *Syk*^{-/-} platelets adhere normally to immobilized fibrinogen [203] and fail to show appropriate aggregation responses in collagen, but thrombin-stimulated responses remain normal [204, 205].

Twelve isoforms of the PKC family are involved in most platelet functions required for thrombus formation [206]. Recent data have demonstrated that individual PKC isoforms play highly specific roles in regulating platelet functions. PKC α is an essential positive regulator of granule secretion and secretion-dependent aggregation [207, 208]. The interaction of PKC β with $\alpha \text{IIb}\beta 3$ is regulated by integrin occupancy, and the interaction is required for platelet $\alpha \text{IIb}\beta 3$ outside-in signaling [209]. *PKC δ* ^{-/-} mice showed that PKC δ is a key negative regulator of filopodial formation, and a lack of PKC δ leads to enhanced platelet aggregation [210]. However, Chari et al. have reported that there is no significant difference in thrombus formation ability in the injured artery in *PKC δ* ^{-/-} mice compared to that in wild-type mice [211]. PKC θ is constitutively associated with $\alpha \text{IIb}\beta 3$ in human and murine platelets [160]. PKC θ is an important positive regulator in signaling between integrin $\alpha \text{IIb}\beta 3$ and the actin cytoskeleton during platelet spreading on fibrinogen [212, 213], but not during spreading on collagen-related peptide (CRP) or collagen [213]. *PKC θ* ^{-/-} mice have shown that PKC θ negatively regulates thrombus formation on collagen under flow [213]. However, *PKC ι/λ* ^{-/-} mice show that PKC ι/λ is dispensable for $\alpha \text{IIb}\beta 3$ bidirectional signaling [206]. Studies on murine Src homology 2 domain-containing

inositol 5-phosphatase (SHIP1) knockout platelets have demonstrated that this enzyme regulates $\alpha \text{IIb}\beta 3$ -mediated platelet spreading through phosphatidylinositol (3,4,5)-triphosphate (PI (3,4,5) P3) and Src family kinases, as well as Lyn and calcium oscillation [214]. PI (3,4,5) P3 binds to Rasa3 and reduces Rasa3 Rap1GAP activity, thus facilitating CalDAG-GEFI-mediated Rap1 activation and regulation of $\alpha \text{IIb}\beta 3$ outside-in signaling [215]. The activation of PI3K and internal calcium pathways are thought to be crucial for $\alpha \text{IIb}\beta 3$ outside-in signaling [216]. *PI3K γ* ^{-/-} platelets have demonstrated a diminished ability to reorganize the cytoskeleton, spread on fibrinogen, and form stable thrombi in vivo using a FeCl₃-induced carotid injury model [217, 218]. The absence of PI3K α leads to a reduction in thrombus size and increased arterial occlusion time but does not alter the tail bleeding time [219]. The E3 protein-ubiquitin ligase c-Cbl associates with the class I PI3K p85 regulatory subunit, regulating $\alpha \text{IIb}\beta 3$ integrin outside-in signaling through Src family kinase (SFKs), Syk, and Pyk2 [19]. *Pyk2*^{-/-} platelets show a significant defect in integrin $\alpha \text{IIb}\beta 3$ outside-in signaling, similar to the loss of c-Cbl or PI3K β activity [220–223]. Group IVA cytosolic phospholipase A₂ (cPLA₂ α) and vimentin, a cPLA₂ α binding partner, are constitutively associated with $\alpha \text{IIb}\beta 3$ in mouse and human platelets [224]. The data from the *cPLA₂ α* ^{-/-} platelets demonstrated that $\alpha \text{IIb}\beta 3$ outside-in signaling was impaired and inside-out signaling was partially impaired [224, 225]. Khatlani et al. recently reported that the interaction of the catalytic subunit of protein phosphatase 2A (PP2Ac) with the adaptor protein Cbl-interacting protein of 85 kDa (CIN85) supports integrin $\alpha \text{IIb}\beta 3$ outside-in signaling by suppressing phosphatase activity [226]. The Rho-family GTPases RhoA [227], Ras-related C3 botulinum toxin substrate 1 (Rac1) [228], and cell division control protein 42 (Cdc42) [229] are important for integrin-mediated platelet shape changes, but their precise role in $\alpha \text{IIb}\beta 3$ outside-in signaling has been controversial [19].

Therapeutic agents targeting integrin $\alpha \text{IIb}\beta 3$ in clinical use

Therapeutic agents targeting integrin $\alpha \text{IIb}\beta 3$, both approved for clinical use and under development, are shown in Table 2. Currently, three therapeutic agents, consisting of integrin $\alpha \text{IIb}\beta 3$ antagonists, the antibody fragment abciximab, and two small molecule inhibitors (eptifibatid and tirofiban), have been approved for clinical use in most countries. Abciximab (Reopro) is the Fab fragment of the mouse/human chimeric monoclonal antibody 7E3 that binds to an epitope near the ligand binding site of integrin $\beta 3$. The steric hindrance resulting from the binding of abciximab to integrin $\alpha \text{IIb}\beta 3$ prevents the interaction of fibrinogen and other ligands with integrin $\alpha \text{IIb}\beta 3$,

Table 2 Therapeutic agents targeting the integrin $\alpha\text{IIb}\beta 3$ molecule in clinical use and preclinical studies

Class	Agent	Synonyms	Status	References
Monoclonal antibody	Abciximab	ReoPro, ClotinaB, CentoRx	Approved	[230]
	YM337	Null	No development reported	[258]
KGD sequence	Eptifibatide	Intrifiban, SB-1, Sch-60936, Integrilin	Approved	[232]
RGD sequence	MK-0852	L-367073	No development reported	[259]
	G4120	Null	No development reported	[260]
	DMP-728	Null	No development reported	[261]
Nonpeptide inhibitors	Tirofiban	L-700462, MK-383, Aggrastat	Approved	[262]
	Lamifiban	Ro-449883	Not approved	[263]
	GR144053	Null	No development reported	[264]
Oral agents	Xemilofiban	SC-54684; SC-54701 is the active component of xemilofiban	Not approved	[265]
	Orbofiban	SC-57099B, CS-511; SC-57101 is the active component of orbofiban	Not approved	[266]
	Sibrafiban	Null	Not approved	[267]
	Lotrafiban	Null	Not approved	[268]
	Lefradafiban	BiBu-104; fradafiban is the active component of lefradafiban	Not approved	[238]
	Roxifiban	DMP754	Not approved	[269]
	Cromafiban	CT-50352	Not approved	[238]
	FK-633	Null	Not approved	[238]
	Elarofiban	RWJ-53308	Not approved	[238, 270]
	SR-121787	Null	Not approved	[238, 271]
	Alnidofibatide	PRP-109891, Klerval	Not approved	[272]
Others	ANTP266	Null	Preclinical studies	[246]
	RUC-1, RUC-2	Null	Preclinical studies	[273, 274]
	PLT/uPA-T	Null	Preclinical studies	[244]
	scFvSCE5-scuPA	Null	Preclinical studies	[243]
	Targ-CD39	Null	Preclinical studies	[275]
	myr-FEEERA	Null	Preclinical studies	[181]
	RGT-containing peptides	Null	Preclinical studies	[196, 197]

interfering with platelet aggregation and thrombosis. Abciximab has a nearly equal affinity for blocking either integrin $\alpha\text{IIb}\beta 3$ or $\alpha\text{v}\beta 3$ [230]. In addition, abciximab also reacts with a member of the $\beta 2$ integrin subfamily of leukocyte integrins, called Mac-1 (CD11b/CD18, $\alpha\text{M}\beta 2$) [231]. This feature gives abciximab anti-inflammatory and antiproliferative properties, but the clinical implications are unclear. Eptifibatide (Integrilin) is an 832 Da cyclic heptapeptide containing a lysine-glycine-aspartic acid (KGD) sequence, based on the structure of snake venom barbourin [232]. Tirofiban (Aggrastat) is a 495 Da synthetic compound (an L-tyrosine derivative) that acts as an RGD mimetic. The EPIC trial showed a reduced frequency

of restenosis in high-risk angioplasty patients who received abciximab infusion [233]. Three phase 3 clinical trials (EPIC, EPILOG, and CAPTURE) showed that abciximab is effective in the prevention of ischemic cardiac complications, either in patients undergoing percutaneous coronary intervention or in patients with unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI) that was unresponsive to conventional therapy [234]. In recent years, tirofiban and eptifibatide have been introduced in clinical practice. Eptifibatide and tirofiban have also been approved for use in unstable angina, as well as angioplasty. The STRATEGY, MULTI-STRATEGY, and EVA-AMI trials demonstrated similar clinical outcomes

between eptifibatide and abciximab in patients undergoing primary angioplasty [230]. Eptifibatide and tirofiban were developed to be used in patients with acute coronary syndrome (ACS) as a bridging therapy to revascularization. Eptifibatide and tirofiban were used directly in the catheterization laboratory immediately prior to PCI [235]. All three integrin α Ib β 3 antagonists are administered intravenously, but several oral active agents have been extensively investigated. Orbofiban, sibrafiban, xemilofiban, lefradafiban, and roxifiban are all experienced on phase II or phase III clinical trials. However, these oral α Ib β 3 antagonists are associated with a prolonged bleeding time, an increase in the incidence of thrombocytopenia, and a 30–35% increase in mortality, including cardiovascular mortality, potentially outweighing the beneficial effects [236]. Orally active antagonists have not yet been approved due to these adverse effects, as well as the fact that oral antagonists have exhibited no significant advantage compared to aspirin in large-scale clinical trials (totaling 33,326 subjects) [237]. For a more in-depth examination of integrin α Ib β 3 antagonists, several comprehensive reviews have been selected for further reading [238–240]. In addition to integrin α Ib β 3 antagonists, some potential therapeutic agents (cilengitide, MRL-123) targeting the integrin α v β 3 molecule have been extensively investigated for anti-cancer or osteoporosis [238].

Innovative agents/concepts targeting integrin α Ib β 3 and its signaling pathways

Because of the marked inhibition of platelet function, integrin α Ib β 3 antagonists can increase bleeding risk, although many studies suggest that these antagonists do not significantly increase the risk of life-threatening bleeding when compared to standard unfractionated heparin [235]. Severe thrombocytopenia is associated with all three currently approved integrin α Ib β 3 antagonists [241]. Thus, integrin α Ib β 3 antagonists must act in a narrow therapeutic window to prevent uncontrolled bleeding. The integrin α Ib β 3 antagonists currently in clinical use have been reported to cause conformational changes of α Ib β 3, inducing fibrinogen binding (priming) and eliciting outside-in signaling, thereby causing paradoxical platelet activation [242]. Currently, three novel and attractive concepts for avoiding bleeding risk are under development. (1) The single-chain variable fragment (scFv) of anti-integrin α Ib β 3 fused to an anti-coagulant, fibrinolytic drugs, and CD39 is being developed. In preclinical studies, the prodrugs PLT/uPA-T and scFvSCE5-scuPA effectively inhibited thrombosis without affecting hemostasis [243, 244]. Targ-CD39 (CD39 recombinantly fused to an activated α Ib β 3-specific scFv) also demonstrates strong antithrombotic potency without

hemostatic disturbance [245]. (2) Small molecules, such as RUC-1 and RUC-2, which selectively inhibit α Ib β 3 binding to fibrinogen to avoid a conformational change of the integrin α Ib β 3, are also being developed. Unlike classic agents, RUC-1 and RUC-2 bind to the metal ion binding site of β 3 to inhibit fibrinogen binding. RUC-1 and RUC-2 do not induce a conformational change of integrin β 3. As a result, they do not “prime” α Ib β 3 to bind its ligands. These small molecules that selectively inhibit fibrinogen binding to integrin α Ib β 3 have shown potent antithrombotic effects with low bleeding risk [246, 247]. (3) Targeting the integrin α Ib β 3 outside-in signaling pathways instead of the integrin α Ib β 3 molecule itself is another approach. Transgenic animals with impaired integrin α Ib β 3 outside-in signaling displayed a similar phenotype of reduced thrombosis potential, without excessive bleeding [248]. Thus, blocking integrin α Ib β 3 outside-in signaling has a potential advantage for the design of new antithrombotic therapies. A major advantage of targeting integrin α Ib β 3 outside-in signaling may be unaffected primary platelet adhesion and the first wave of reversible aggregation, which is critical for hemostasis but can reduce the size of a thrombus to prevent vessel occlusion [181, 196]. A recent study showed that the myr-FEEERA peptide selectively inhibits the G α 13-integrin β 3 interaction, ultimately impairing Src activation and thereby inhibiting integrin α Ib β 3 outside-in signaling [181]. Both eptifibatide and the myr-FEEERA peptide inhibit laser-induced arteriolar thrombosis and FeCl₃-induced occlusive carotid artery thrombosis. Eptifibatide also dramatically prolongs tail bleeding and increases blood loss; however, the myr-FEEERA peptide had no such adverse side effects [181]. Our studies have demonstrated that RGT-containing peptides have the ability to selectively inhibit integrin α Ib β 3 outside-in signaling through physical dissociation of the Src/ β 3 interaction in platelets [196, 197]. The results from ex vivo flow-based assays show that RGT-containing peptides inhibit thrombus formation under high shear rates but not under intermediate or low shear rates. The RGT peptide, its derivatives, and its analogs may have the potential to be developed into novel antithrombotic agents that specifically disrupt integrin α Ib β 3 outside-in signaling. However, it is still important to consider and investigate potential off-target effects caused by selective targeting of the G α 13- β 3 and Src- β 3 interactions.

Conclusions

The development of proteomics, biophysics, and gene knockout/knockin technologies has uncovered an increasing number of proteins that participate in the bidirectional signaling of integrin α Ib β 3 and has begun to shed light on their mechanisms and roles in regulating integrin

α IIb β 3 signaling. Given the importance of integrin α IIb β 3 bidirectional signaling in maintaining proper platelet function, examining the complex regulatory relationship between these interacting proteins can prove immensely important for understanding the mechanisms of platelet activity, as well as for developing new therapies for cancer and thrombosis based on a deeper knowledge of the underlying physiology. Until now, the complex stoichiometric and spatiotemporal dynamics between integrin α IIb β 3 and its regulatory proteins have remained obscure, but promising new techniques have already presented new opportunities to learn more. Considerable efforts are still needed to fully explore how integrin α IIb β 3 interacts with its regulatory proteins, how its regulatory proteins interact with one another in space and time, and how therapeutic agents targeting integrin α IIb β 3 and its pathways can provide therapeutic benefits while minimizing adverse side effects.

Abbreviations

5-HT: 5-Hydroxytryptamine; ACS: Acute coronary syndrome; ADAP: A hematopoietic-specific adapter protein; ADP: Adenosine diphosphate; BiFC: Bimolecular fluorescence complementation; CalDAG-GEFI: Ca²⁺ diacylglycerol guanine-nucleotide-exchange factor I; Cdc42: Cell division control protein 42; CEACAM-1: Carcinoembryonic antigen-related cell adhesion molecule-1; CHO: Chinese hamster ovary; CIB1: Calcium- and integrin-binding protein 1; CIN85: Cbl-interacting protein of 85 kDa; cPLA₂ α : Group IVA cytosolic phospholipase A₂; CRP: Collagen-related peptide; Csk: C-terminal Src kinase; CTX: Cortical thymocyte marker of *Xenopus*; Dab2: Disabled-2; DAG: Diacylglycerol; Dok: Docking protein; EPIC: European Prevalence of Infection in Intensive Care; ESAM: Endothelial cell specific adhesion molecule; FAK: Focal adhesion kinase; FcR γ : Fc receptor γ -chain; FERM: 4.1, Ezrin, radixin, moesin; Gas6: Growth arrest specific protein 6; GP: Glycoprotein; GPCR: G protein-coupled seven-transmembrane domain receptor; Grb2: Growth factor receptor bound protein 2; GT: Glanzmann's thrombasthenia; HPC: Hematopoietic progenitor cell; HSC: Hematopoietic stem cell; IBS: Integrin-binding site; ICLn: Chloride channel regulatory protein; ILK: Integrin-linked kinase; IP3: Inositol (1,4,5)-triphosphate; IP3-R: P3 receptor; IPP: ILK/PINCH/parvin; ITAM: Immunoreceptor tyrosine-based activation motif; ITIM: Immunoreceptor tyrosine-based inhibitory motif; JAM-A: Junctional adhesion molecule-A; KGD: Lysine-glycine-aspartic acid; Lnk: Lymphocyte adaptor protein; mAb: Monoclonal antibody; MEK3: Mitogen-activated protein kinase/extracellular-regulated kinase kinase kinase-3; MRL: Mig-10/RIAM/lamellipodin; NLRP3: NACHT, LRR, and PYD domain-containing protein 3; NSTMI: Non-ST-elevation myocardial infarction; PCI: Percutaneous coronary intervention; PDK1: 3-Phosphoinositide-dependent protein kinase-1; PECAM-1: Platelet endothelial cell adhesion molecule-1; PI3K: Phosphatidylinositol-3-kinase; PI-4,5-P: Phosphatidylinositol (4,5)-bisphosphate; PIPK1 γ : Phosphatidylinositol 4-phosphate 5-kinase isoform 1 γ ; PKC: Protein kinase C; PMA: Phorbol 12-myristate 13-acetate; PP1 γ : Catalytic subunit of protein phosphatase 1 γ ; PP2A α : Catalytic subunit of protein phosphatase 2A; PPAR γ : Peroxisome proliferator-activated receptor γ ; PTB: Phosphotyrosine-binding domain; PTEN: Phosphatase and tensin homolog deleted on chromosome ten; PTP-1B: Protein-tyrosine phosphatase-1B; PXN: Paxillin; Pyk2: Proline-rich tyrosine kinase 2; Rac1: Ras-related C3 botulinum toxin substrate 1; RGT: Arginine-glycine-threonine; RhoA: Rho-family GTPase; RIAM: Rap1-GTP-interacting adaptor molecule; SFK: Src family kinase; SHBG: Sex hormone binding globulin; Shc: Src homology 2 domain-containing transforming protein; SHIP: Src homology 2 domain-containing inositol 5-phosphatase; Sin1: Stress-activated protein kinase-interacting protein; SLAM: Signaling lymphocyte activation molecule; SLP-76: SH2 domain-containing leukocyte protein of 76 kDa; Syk: Spleen tyrosine kinase; TM: Transmembrane; TSSC6: Tumor suppressing subtransferable candidate 6; TXA2: Thromboxane A2; UA: Unstable angina; UV: Ultraviolet; VEGF: Vascular endothelial growth factor; VPS33B: Vacuolar protein sorting-associated

protein 33b; vWF: von Willebrand factor; WASP: Wiskott-Aldrich syndrome protein

Acknowledgments

We thank all of our laboratory members for helpful discussion.

Funding

This study was supported by grants from the National Natural Science Foundation of China (81820108004, 81470305, 81670127, 81770624, and 81860490).

Availability of data and materials

All data and materials supporting the conclusions of this study have been included within the article.

Authors' contributions

JH, XL, and XX were responsible for the conception and drafting of the manuscript and figures. JJ reviewed the articles to prepare this manuscript and participated in the discussion. All authors revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. ²Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, China. ³Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. ⁴Department of Hematology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China. ⁵Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA. ⁶Department of Pathology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. ⁷Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. ⁸State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Collaborative Innovation Center of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. ⁹Sino-French Research Centre for Life Sciences and Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. ¹⁰Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. ¹¹Clinical Prenatal Diagnosis Center, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Received: 23 December 2018 Accepted: 21 February 2019

Published online: 07 March 2019

References

- Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell*. 2002;110(6):673–87.
- Staatz WD, Rajpara SM, Wayner EA, Carter WG, Santoro SA. The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mg²⁺-dependent adhesion of platelets to collagen. *J Cell Biol*. 1989; 108(5):1917–24.
- Piotrowicz RS, Orzechowski RP, Nugent DJ, Yamada KY, Kunicki TJ. Glycoprotein Ic-IIa functions as an activation-independent fibronectin receptor on human platelets. *J Cell Biol*. 1988;106(4):1359–64.

4. Ill CR, Engvall E, Ruoslahti E. Adhesion of platelets to laminin in the absence of activation. *J Cell Biol.* 1984;99(6):2140–5.
5. Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. *Nature.* 1988;336(6198):487–9.
6. Bennett JS, Chan C, Vilaire G, Mousa SA, DeGrado WF. Agonist-activated $\alpha v \beta 3$ on platelets and lymphocytes binds to the matrix protein osteopontin. *J Biol Chem.* 1997;272(13):8137–40.
7. Paul BZ, Vilaire G, Kunapuli SP, Bennett JS. Concurrent signaling from Gq α - and G αi -coupled pathways is essential for agonist-induced $\alpha v \beta 3$ activation on human platelets. *J Thromb Haemost.* 2003;1(4):814–20.
8. Lavergne M, Janus-Bell E, Schaff M, Gachet C, Mangin PH. Platelet integrins in tumor metastasis: do they represent a therapeutic target? *Cancers (Basel).* 2017;9(10):133.
9. Springer TA, Zhu J, Xiao T. Structural basis for distinctive recognition of fibrinogen γC peptide by the platelet integrin $\alpha IIb \beta 3$. *J Cell Biol.* 2008;182(4):791–800.
10. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. *Br J Haematol.* 1974;28(2):253–60.
11. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. *Blood.* 1990;75(7):1383–95.
12. Zhou L, Jiang M, Shen H, You T, Ding Z, Cui Q, et al. Clinical and molecular insights into Glanzmann's thrombasthenia in China. *Clin Genet.* 2018;94(2):213–20.
13. Qiao J, Wu X, Luo Q, Wei G, Xu M, Wu Y, et al. NLRP3 regulates platelet integrin $\alpha IIb \beta 3$ outside-in signaling, hemostasis and arterial thrombosis. *Haematologica.* 2018;103(9):1568–76.
14. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. *Blood.* 1996;88(3):907–14.
15. Woods VL Jr, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. *J Biol Chem.* 1986;261(32):15242–51.
16. Wencel-Drake JD, Plow EF, Kunicki TJ, Woods VL, Keller DM, Ginsberg MH. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. *Am J Pathol.* 1986;124(2):324–34.
17. Amirkhosravi A, Amaya M, Siddiqui F, Biggerstaff JP, Meyer TV, Francis JL. Blockade of GPIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. *Platelets.* 1999;10(5):285–92.
18. Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. *Cold Spring Harb Perspect Biol.* 2011;3(3):a004994.
19. Durrant TN, van den Bosch MT, Hers I. Integrin $\alpha IIb \beta 3$ outside-in signaling. *Blood.* 2017;130(14):1607–19.
20. Ye F, Kim C, Ginsberg MH. Molecular mechanism of inside-out integrin regulation. *J Thromb Haemost.* 2011;9(Suppl 1):20–5.
21. Ginsberg MH. Integrin activation. *BMB Rep.* 2014;47(12):655–9.
22. Ye F, Snider AK, Ginsberg MH. Talin and kindlin: the one-two punch in integrin activation. *Front Med.* 2014;8(1):6–16.
23. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. *Nat Rev Mol Cell Biol.* 2010;11(4):288–300.
24. Nieswandt B, Varga-Szabo D, Elvers M. Integrins in platelet activation. *J Thromb Haemost.* 2009;7(Suppl 1):206–9.
25. Goksoy E, Ma YQ, Wang X, Kong X, Perera D, Plow EF, et al. Structural basis for the autoinhibition of talin in regulating integrin activation. *Mol Cell.* 2008;31(1):124–33.
26. Anthis NJ, Wegener KL, Ye F, Kim C, Goult BT, Lowe ED, et al. The structure of an integrin/talin complex reveals the basis of inside-out signal transduction. *EMBO J.* 2009;28(22):3623–32.
27. Critchley DR. Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion. *Biochem Soc Trans.* 2004;32(Pt 5):831–6.
28. Garcia-Alvarez B, de Pereda JM, Calderwood DA, Ulmer TS, Critchley D, Campbell ID, et al. Structural determinants of integrin recognition by talin. *Mol Cell.* 2003;11(1):49–58.
29. Di Paolo G, Pellegrini L, Letinic K, Cestra G, Zoncu R, Voronov S, et al. Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 γ by the FERM domain of talin. *Nature.* 2002;420(6911):85–9.
30. Ling K, Doughman RL, Firestone AJ, Bunce MW, Anderson RA. Type 1 γ phosphatidylinositol phosphate kinase targets and regulates focal adhesions. *Nature.* 2002;420(6911):89–93.
31. Wegener KL, Basran J, Bagshaw CR, Campbell ID, Roberts GC, Critchley DR, et al. Structural basis for the interaction between the cytoplasmic domain of the hyaluronate receptor layilin and the talin F3 subdomain. *J Mol Biol.* 2008;382(1):112–26.
32. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL. Interaction of focal adhesion kinase with cytoskeletal protein talin. *J Biol Chem.* 1995;270(28):16995–9.
33. Hemmings L, Rees DJ, Ohanian V, Bolton SJ, Gilmore AP, Patel B, et al. Talin contains three actin-binding sites each of which is adjacent to a vinculin-binding site. *J Cell Sci.* 1996;109(Pt 11):2715–26.
34. Moes M, Rodius S, Coleman SJ, Monkley SJ, Goormaghtigh E, Tremuth L, et al. The integrin binding site 2 (IBS2) in the talin rod domain is essential for linking integrin β subunits to the cytoskeleton. *J Biol Chem.* 2007;282(23):17280–8.
35. Gingras AR, Ziegler WH, Frank R, Barsukov IL, Roberts GC, Critchley DR, et al. Mapping and consensus sequence identification for multiple vinculin binding sites within the talin rod. *J Biol Chem.* 2005;280(44):37217–24.
36. Nakazawa T, Tadokoro S, Kamae T, Kiyomizu K, Kashiwagi H, Honda S, et al. Agonist stimulation, talin-1, and kindlin-3 are crucial for $\alpha IIb \beta 3$ activation in a human megakaryoblastic cell line, CMK. *Exp Hematol.* 2013;41(11):79–90.e1.
37. Haling JR, Monkley SJ, Critchley DR, Petrich BG. Talin-dependent integrin activation is required for fibrin clot retraction by platelets. *Blood.* 2011;117(5):1719–22.
38. Kasirer-Friede A, Kang J, Kahner B, Ye F, Ginsberg MH, Shattil SJ. ADAP interactions with talin and kindlin promote platelet integrin $\alpha IIb \beta 3$ activation and stable fibrinogen binding. *Blood.* 2014;123(20):3156–65.
39. Ye F, Hu G, Taylor D, Ratnikov B, Bobkov AA, McLean MA, et al. Recreation of the terminal events in physiological integrin activation. *J Cell Biol.* 2010;188(1):157–73.
40. Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO, Ginsberg MH. The talin head domain binds to integrin β subunit cytoplasmic tails and regulates integrin activation. *J Biol Chem.* 1999;274(40):28071–4.
41. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, et al. Talin binding to integrin β tails: a final common step in integrin activation. *Science.* 2003;302(5642):103–6.
42. Petrich BG, Fogelstrand P, Partridge AW, Yousefi N, Ablooglu AJ, Shattil SJ, et al. The antithrombotic potential of selective blockade of talin-dependent integrin $\alpha IIb \beta 3$ (platelet GPIIb-IIIa) activation. *J Clin Invest.* 2007;117(8):2250–9.
43. Petrich BG, Marchese P, Ruggeri ZM, Spiess S, Weichert RA, Ye F, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. *J Exp Med.* 2007;204(13):3103–11.
44. Nieswandt B, Moser M, Pleines I, Varga-Szabo D, Monkley S, Critchley D, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. *J Exp Med.* 2007;204(13):3113–8.
45. Stefanini L, Ye F, Snider AK, Sarabakhsh K, Piatt R, Paul DS, et al. A talin mutant that impairs talin-integrin binding in platelets decelerates $\alpha IIb \beta 3$ activation without pathological bleeding. *Blood.* 2014;123(17):2722–31.
46. Bledzka K, Bialkowska K, Nie H, Qin J, Byzova T, Wu C, et al. Tyrosine phosphorylation of integrin $\beta 3$ regulates kindlin-2 binding and integrin activation. *J Biol Chem.* 2010;285(40):30370–4.
47. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. *Nat Med.* 2008;14(3):325–30.
48. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of $\beta 3$ integrins. *J Cell Biol.* 2008;181(3):439–46.
49. Montanez E, Ussar S, Schifferer M, Bosl M, Zent R, Moser M, et al. Kindlin-2 controls bidirectional signaling of integrins. *Genes Dev.* 2008;22(10):1325–30.
50. Klapproth S, Moretti FA, Zeiler M, Ruppert R, Breithaupt U, Mueller S, et al. Minimal amounts of kindlin-3 suffice for basal platelet and leukocyte functions in mice. *Blood.* 2015;126(24):2592–600.
51. Gao J, Huang M, Lai J, Mao K, Sun P, Cao Z, et al. Kindlin supports platelet integrin $\alpha IIb \beta 3$ activation by interacting with paxillin. *J Cell Sci.* 2017;130(21):3764–75.
52. Harburger DS, Bouaouina M, Calderwood DA. Kindlin-1 and -2 directly bind the C-terminal region of β integrin cytoplasmic tails and exert integrin-specific activation effects. *J Biol Chem.* 2009;284(17):11485–97.
53. Svensson L, Howarth K, McDowall A, Patzak I, Evans R, Ussar S, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. *Nat Med.* 2009;15(3):306–12.

54. Moser M, Legate KR, Zent R, Fassler R. The tail of integrins, talin, and kindlins. *Science*. 2009;324(5929):895–9.
55. Lai-Cheong JE, Parsons M, McGrath JA. The role of kindlins in cell biology and relevance to human disease. *Int J Biochem Cell Biol*. 2010;42(5):595–603.
56. Meves A, Stremmel C, Gottschalk K, Fassler R. The Kindlin protein family: new members to the club of focal adhesion proteins. *Trends Cell Biol*. 2009;19(10):504–13.
57. Ussar S, Wang HV, Linder S, Fassler R, Moser M. The Kindlins: subcellular localization and expression during murine development. *Exp Cell Res*. 2006;312(16):3142–51.
58. Bialkowska K, Ma YQ, Bledzka K, Sossey-Alaoui K, Lzem L, Zhang X, et al. The integrin co-activator Kindlin-3 is expressed and functional in a non-hematopoietic cell, the endothelial cell. *J Biol Chem*. 2010;285(24):18640–9.
59. Zhou C, Song S, Zhang J. A novel 3017-bp deletion mutation in the FERMT1 (KIND1) gene in a Chinese family with Kindler syndrome. *Br J Dermatol*. 2009;160(5):1119–22.
60. Techanukul T, Sethuraman G, Zlotogorski A, Horev L, Macarov M, Trainer A, et al. Novel and recurrent FERMT1 gene mutations in Kindler syndrome. *Acta Derm Venereol*. 2011;91(3):267–70.
61. Kuijpers TW, van de Vijver E, Weterman MA, de Boer M, Tool AT, van den Berg TK, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. *Blood*. 2009;113(19):4740–6.
62. Nagy M, Mastenbroek TG, Mattheij NJA, de Witt S, Clemetson KJ, Kirschner J, et al. Variable impairment of platelet functions in patients with severe, genetically linked immune deficiencies. *Haematologica*. 2018;103(3):540–9.
63. Rognoni E, Ruppert R, Fassler R. The kindlin family: functions, signaling properties and implications for human disease. *J Cell Sci*. 2016;129(1):17–27.
64. McDowall A, Svensson L, Stanley P, Patzak I, Chakravarty P, Howarth K, et al. Two mutations in the KINDLIN3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro. *Blood*. 2010;115(23):4834–42.
65. Wang P, Zhan J, Song J, Wang Y, Fang W, Liu Z, et al. Differential expression of Kindlin-1 and Kindlin-2 correlates with esophageal cancer progression and epidemiology. *Sci China Life Sci*. 2017;60(11):1214–22.
66. Dowling JJ, Gibbs E, Russell M, Goldman D, Minarcik J, Golden JA, et al. Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. *Circ Res*. 2008;102(4):423–31.
67. Pluskota E, Dowling JJ, Gordon N, Golden JA, Szpak D, West XZ, et al. The integrin coactivator kindlin-2 plays a critical role in angiogenesis in mice and zebrafish. *Blood*. 2011;117(18):4978–87.
68. Goult BT, Bouaouina M, Harburger DS, Bate N, Patel B, Anthis NJ, et al. The structure of the N-terminus of kindlin-1: a domain important for α IIb β 3 integrin activation. *J Mol Biol*. 2009;394(5):944–56.
69. Bledzka K, Liu J, Xu Z, Perera HD, Yadav SP, Bialkowska K, et al. Spatial coordination of kindlin-2 with talin head domain in interaction with integrin β cytoplasmic tails. *J Biol Chem*. 2012;287(29):24585–94.
70. Anthis NJ, Haling JR, Oxley CL, Memo M, Wegener KL, Lim CJ, et al. β Integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation. *J Biol Chem*. 2009;284(52):36700–10.
71. Oxley CL, Anthis NJ, Lowe ED, Vakonakis I, Campbell ID, Wegener KL. An integrin phosphorylation switch: the effect of β 3 integrin tail phosphorylation on Dok1 and talin binding. *J Biol Chem*. 2008;283(9):5420–6.
72. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. *Arterioscler Thromb Vasc Biol*. 2010;30(12):2341–9.
73. Li H, Deng Y, Sun K, Yang H, Liu J, Wang M, et al. Structural basis of kindlin-mediated integrin recognition and activation. *Proc Natl Acad Sci U S A*. 2017;114(35):9349–54.
74. Fukuda K, Bledzka K, Yang J, Perera HD, Plow EF, Qin J. Molecular basis of kindlin-2 binding to integrin-linked kinase pseudokinase for regulating cell adhesion. *J Biol Chem*. 2014;289(41):28363–75.
75. Huet-Calderwood C, Brahme NN, Kumar N, Stiegler AL, Raghavan S, Boggon TJ, et al. Differences in binding to the ILK complex determines kindlin isoform adhesion localization and integrin activation. *J Cell Sci*. 2014;127(Pt 19):4308–21.
76. Kasirer-Friede A, Moran B, Nagrampa-Orje J, Swanson K, Ruggeri ZM, Schraven B, et al. ADAP is required for normal α IIb β 3 activation by VWF/GP Ib-IX-V and other agonists. *Blood*. 2007;109(3):1018–25.
77. Kasirer-Friede A, Ruggeri ZM, Shattil SJ. Role for ADAP in shear flow-induced platelet mechanotransduction. *Blood*. 2010;115(11):2274–82.
78. Theodosiou M, Widmaier M, Bottcher RT, Rognoni E, Veelders M, Bharadwaj M, et al. Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin. *Elife*. 2016;5:e10130.
79. Sakata A, Ohmori T, Nishimura S, Suzuki H, Madoiwa S, Mimuro J, et al. Paxillin is an intrinsic negative regulator of platelet activation in mice. *Thromb J*. 2014;12(1):1.
80. Honda S, Shirogami-Ikejima H, Tadokoro S, Maeda Y, Kinoshita T, Tomiyama Y, et al. Integrin-linked kinase associated with integrin activation. *Blood*. 2009;113(21):5304–13.
81. Shattil SJ, O'Toole T, Eigenthaler M, Thon V, Williams M, Babior BM, et al. β 3-Endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin β 3 subunit. *J Cell Biol*. 1995;131(3):807–16.
82. Kashiwagi H, Schwartz MA, Eigenthaler M, Davis KA, Ginsberg MH, Shattil SJ. Affinity modulation of platelet integrin α IIb β 3 by β 3-endonexin, a selective binding partner of the β 3 integrin cytoplasmic tail. *J Cell Biol*. 1997;137(6):1433–43.
83. Tsuboi S. Calcium integrin-binding protein activates platelet integrin α IIb β 3. *J Biol Chem*. 2002;277(3):1919–23.
84. Yuan W, Leisner TM, McFadden AW, Wang Z, Larson MK, Clark S, et al. CIB1 is an endogenous inhibitor of agonist-induced integrin α IIb β 3 activation. *J Cell Biol*. 2006;172(2):169–75.
85. Larkin D, Murphy D, Reilly DF, Cahill M, Sattler E, Harriott P, et al. ICln, a novel integrin α IIb β 3-associated protein, functionally regulates platelet activation. *J Biol Chem*. 2004;279(26):27286–93.
86. Gushiken FC, Hyojeong H, Pradhan S, Langlois KW, Alrehani N, Cruz MA, et al. The catalytic subunit of protein phosphatase 1 γ regulates thrombin-induced murine platelet α IIb β 3 function. *PLoS One*. 2009;4(12):e8304.
87. Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Honda S, et al. Vinculin activates inside-out signaling of integrin α IIb β 3 in Chinese hamster ovary cells. *Biochem Biophys Res Commun*. 2010;400(3):323–8.
88. Tucker KL, Sage T, Stevens JM, Jordan PA, Jones S, Barrett NE, et al. A dual role for integrin-linked kinase in platelets: regulating integrin function and α -granule secretion. *Blood*. 2008;112(12):4523–31.
89. Jones CI, Tucker KL, Sasikumar P, Sage T, Kaiser WJ, Moore C, et al. Integrin-linked kinase regulates the rate of platelet activation and is essential for the formation of stable thrombi. *J Thromb Haemost*. 2014;12(8):1342–52.
90. Pasquet JM, Noury M, Nurden AT. Evidence that the platelet integrin α IIb β 3 is regulated by the integrin-linked kinase, ILK, in a PI3-kinase dependent pathway. *Thromb Haemost*. 2002;88(1):115–22.
91. Sadoul K, Vignoud L, Mossuz P, Block MR. Proteolysis leads to the appearance of the long form of β 3-endonexin in human platelets. *Exp Cell Res*. 2005;305(2):427–35.
92. Kracun D, Riess F, Kanchev I, Gawaz M, Gorlach A. The β 3-integrin binding protein β 3-endonexin is a novel negative regulator of hypoxia-inducible factor-1. *Antioxid Redox Signal*. 2014;20(13):1964–76.
93. Naik MU, Naik TU, Summer R, Naik UP. Binding of CIB1 to the α IIb tail of α IIb β 3 is required for FAK recruitment and activation in platelets. *PLoS One*. 2017;12(5):e0176602.
94. Lagarrigue F, Vikas Anekal P, Lee HS, Bachir AI, Ablack JN, Horwitz AF, et al. A RIAM/lamellipodin-talin-integrin complex forms the tip of sticky fingers that guide cell migration. *Nat Commun*. 2015;6:8492.
95. Mitsios JV, Prevost N, Kasirer-Friede A, Gutierrez E, Groisman A, Abrams CS, et al. What is vinculin needed for in platelets? *J Thromb Haemost*. 2010;8(10):2294–304.
96. Kato A, Kawamata N, Tamayose K, Egashira M, Miura R, Fujimura T, et al. Ancient ubiquitous protein 1 binds to the conserved membrane-proximal sequence of the cytoplasmic tail of the integrin α subunits that plays a crucial role in the inside-out signaling of α IIb β 3. *J Biol Chem*. 2002;277(32):28934–41.
97. Kiema T, Lad Y, Jiang P, Oxley CL, Baldassarre M, Wegener KL, et al. The molecular basis of filamin binding to integrins and competition with talin. *Mol Cell*. 2006;21(3):337–47.
98. McCleverty CJ, Lin DC, Liddington RC. Structure of the PTB domain of tensin1 and a model for its recruitment to fibrillar adhesions. *Protein Sci*. 2007;16(6):1223–9.
99. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, et al. Structural basis of integrin activation by talin. *Cell*. 2007;128(1):171–82.
100. Denofrio JC, Yuan W, Temple BR, Gentry HR, Parise LV. Characterization of calcium- and integrin-binding protein 1 (CIB1) knockout platelets: potential compensation by CIB family members. *Thromb Haemost*. 2008;100(5):847–56.
101. Naik MU, Nigam A, Manrai P, Millili P, Czymbek K, Sullivan M, et al. CIB1 deficiency results in impaired thrombosis: the potential role of

- CIB1 in outside-in signaling through integrin $\alpha\text{IIb}\beta\text{3}$. *J Thromb Haemost*. 2009;7(11):1906–14.
102. Izard T, Vonrhein C. Structural basis for amplifying vinculin activation by talin. *J Biol Chem*. 2004;279(26):27667–78.
103. Calderwood DA, Fujioka Y, de Pereda JM, Garcia-Alvarez B, Nakamoto T, Margolis B, et al. Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. *Proc Natl Acad Sci U S A*. 2003;100(5):2272–7.
104. Chatterjee D, D'Souza A, Zhang Y, Bin W, Tan SM, Bhattacharjya S. Interaction analyses of 14-3-3 ζ , Dok1, and phosphorylated integrin β cytoplasmic tails reveal a bi-molecular switch in integrin regulation. *J Mol Biol*. 2018;430(21):4419–30.
105. Niki M, Nayak MK, Jin H, Bhasin N, Plow EF, Pandolfi PP, et al. Dok-1 negatively regulates platelet integrin $\alpha\text{IIb}\beta\text{3}$ outside-in signalling and inhibits thrombosis in mice. *Thromb Haemost*. 2016;115(5):969–78.
106. Hugan SC, Spring CM, Schoenwaelder SM, Sturgeon S, Alwis I, Yuan Y, et al. Dok-2 adaptor protein regulates the shear-dependent adhesive function of platelet integrin $\alpha\text{IIb}\beta\text{3}$ in mice. *J Biol Chem*. 2014;289(8):5051–60.
107. Liu J, Das M, Yang J, Ithychanda SS, Yakubenko VP, Plow EF, et al. Structural mechanism of integrin inactivation by filamin. *Nat Struct Mol Biol*. 2015;22(5):383–9.
108. Berrou E, Adam F, Lebret M, Planche V, Fergelot P, Issertial O, et al. Gain-of-function mutation in filamin A potentiates platelet integrin $\alpha\text{IIb}\beta\text{3}$ activation. *Arterioscler Thromb Vasc Biol*. 2017;37(6):1087–97.
109. Tadokoro S, Nakazawa T, Kamae T, Kiyomizu K, Kashiwagi H, Honda S, et al. A potential role for α -actinin in inside-out $\alpha\text{IIb}\beta\text{3}$ signaling. *Blood*. 2011;117(1):250–8.
110. Legate KR, Fassler R. Mechanisms that regulate adaptor binding to β -integrin cytoplasmic tails. *J Cell Sci*. 2009;122(Pt 2):187–98.
111. Shams H, Mofrad MRK. α -Actinin induces a kink in the transmembrane domain of β3 -integrin and impairs activation via talin. *Biophys J*. 2017;113(4):948–56.
112. Vanhoorelbeke K, Ullrichs H, Van de Walle G, Fontayne A, Deckmyn H. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. *Curr Pharm Des*. 2007;13(26):2684–97.
113. Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activation. *Blood*. 2014;124(13):2013–24.
114. Severin S, Nash CA, Mori J, Zhao Y, Abram C, Lowell CA, et al. Distinct and overlapping functional roles of Src family kinases in mouse platelets. *J Thromb Haemost*. 2012;10(8):1631–45.
115. Li Z, Zhang G, Liu J, Stojanovic A, Ruan C, Lowell CA, et al. An important role of the SRC family kinase Lyn in stimulating platelet granule secretion. *J Biol Chem*. 2010;285(17):12559–70.
116. Reddy KB, Smith DM, Plow EF. Analysis of Fyn function in hemostasis and $\alpha\text{IIb}\beta\text{3}$ -integrin signaling. *J Cell Sci*. 2008;121(Pt 10):1641–8.
117. Geue S, Walker-Allgaier B, Eissler D, Tegtmeyer R, Schaub M, Lang F, et al. Doxepin inhibits GPVI-dependent platelet Ca²⁺ signaling and collagen-dependent thrombus formation. *Am J Physiol Cell Physiol*. 2017;312(6):C765–C74.
118. Suzuki-Inoue K, Inoue O, Frampton J, Watson SP. Murine GPVI stimulates weak integrin activation in PLC $\gamma\text{2}^{-/-}$ platelets: involvement of PLC γ1 and PI3-kinase. *Blood*. 2003;102(4):1367–73.
119. Ozaki Y, Asazuma N, Suzuki-Inoue K, Berndt MC. Platelet GPIb-IX-V-dependent signaling. *J Thromb Haemost*. 2005;3(8):1745–51.
120. Woulfe D, Jiang H, Mortenson R, Yang J, Brass LF. Activation of Rap1B by G(i) family members in platelets. *J Biol Chem*. 2002;277(26):23382–90.
121. Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. *J Thromb Haemost*. 2009;7(7):1057–66.
122. Cifuni SM, Wagner DD, Bergmeier W. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin $\alpha\text{IIb}\beta\text{3}$ in platelets. *Blood*. 2008;112(5):1696–703.
123. Piatt R, Paul DS, Lee RH, McKenzie SE, Parise LV, Cowley DO, et al. Mice expressing low levels of CalDAG-GEFI exhibit markedly impaired platelet activation with minor impact on hemostasis. *Arterioscler Thromb Vasc Biol*. 2016;36(9):1838–46.
124. Kato H, Nakazawa Y, Kurokawa Y, Kashiwagi H, Morikawa Y, Morita D, et al. Human CalDAG-GEFI deficiency increases bleeding and delays $\alpha\text{IIb}\beta\text{3}$ activation. *Blood*. 2016;128(23):2729–33.
125. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. *Nat Med*. 2004;10(9):982–6.
126. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. *J Thromb Haemost*. 2010;8(3):454–62.
127. Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, et al. Reconstructing and deconstructing agonist-induced activation of integrin $\alpha\text{IIb}\beta\text{3}$. *Curr Biol*. 2006;16(18):1796–806.
128. Konopatskaya O, Gilio K, Harper MT, Zhao Y, Cosemans JM, Karim ZA, et al. PKC α regulates platelet granule secretion and thrombus formation in mice. *J Clin Invest*. 2009;119(2):399–407.
129. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC 2nd. Rap1b is required for normal platelet function and hemostasis in mice. *J Clin Invest*. 2005;115(3):680–7.
130. Lee HS, Lim CJ, Puzon-McLaughlin W, Shattil SJ, Ginsberg MH. RIAM activates integrins by linking talin to ras GTPase membrane-targeting sequences. *J Biol Chem*. 2009;284(8):5119–27.
131. Stritt S, Wolf K, Lorenz V, Vogtle T, Gupta S, Bosl MR, et al. Rap1-GTP-interacting adaptor molecule (RIAM) is dispensable for platelet integrin activation and function in mice. *Blood*. 2015;125(2):219–22.
132. Watanabe N, Bodin L, Pandey M, Krause M, Coughlin S, Boussiotis VA, et al. Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin $\alpha\text{IIb}\beta\text{3}$. *J Cell Biol*. 2008;181(7):1211–22.
133. Zhu L, Yang J, Bromberger T, Holly A, Lu F, Liu H, et al. Structure of Rap1b bound to talin reveals a pathway for triggering integrin activation. *Nat Commun*. 2017;8(1):1744.
134. Lagarrigue F, Gingras AR, Paul DS, Valadez AJ, Cuevas MN, Sun H, et al. Rap1 binding to the talin 1 F0 domain makes a minimal contribution to murine platelet GPIIb-IIIa activation. *Blood Adv*. 2018;2(18):2358–68.
135. Srinivasan S, Schiemer J, Zhang X, Chishti AH, Le Breton GC. Ga13 switch region 2 binds to the talin head domain and activates $\alpha\text{IIb}\beta\text{3}$ integrin in human platelets. *J Biol Chem*. 2015;290(41):25129–39.
136. Wee JL, Jackson DE. The Ig-ITIM superfamily member PECAM-1 regulates the “outside-in” signaling properties of integrin $\alpha\text{IIb}\beta\text{3}$ in platelets. *Blood*. 2005;106(12):3816–23.
137. Wong C, Liu Y, Yip J, Chand R, Wee JL, Oates L, et al. CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo. *Blood*. 2009;113(8):1818–28.
138. Jones CI, Sage T, Moraes LA, Vaiyapuri S, Hussain U, Tucker KL, et al. Platelet endothelial cell adhesion molecule-1 inhibits platelet response to thrombin and von Willebrand factor by regulating the internalization of glycoprotein Ib via AKT/glycogen synthase kinase-3/dynamin and integrin $\alpha\text{IIb}\beta\text{3}$. *Arterioscler Thromb Vasc Biol*. 2014;34(9):1968–76.
139. Newland SA, Macaulay IC, Floto AR, de Vet EC, Ouwehand WH, Watkins NA, et al. The novel inhibitory receptor G6B is expressed on the surface of platelets and attenuates platelet function in vitro. *Blood*. 2007;109(11):4806–9.
140. Geer MJ, van Geffen JP, Gopalasingam P, Vogtle T, Smith CW, Heising S, et al. Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis. *Blood*. 2018;132(13):1413–25.
141. Mazharian A, Wang YJ, Mori J, Bem D, Finney B, Heising S, et al. Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function. *Sci Signal*. 2012;5(248):ra78.
142. Hu M, Liu P, Liu Y, Yue M, Wang Y, Wang S, et al. Platelet Shp2 negatively regulates thrombus stability under high shear stress. *J Thromb Haemost*. 2019;17(1):220–31.
143. Naik UP, Ehrlich YH, Kornecki E. Mechanisms of platelet activation by a stimulatory antibody: cross-linking of a novel platelet receptor for monoclonal antibody F11 with the Fc γRII receptor. *Biochem J*. 1995; 310(Pt 1):155–62.
144. Nasdala I, Wolburg-Buchholz K, Wolburg H, Kuhn A, Ebnet K, Brachtendorf G, et al. A transmembrane tight junction protein selectively expressed on endothelial cells and platelets. *J Biol Chem*. 2002;277(18):16294–303.
145. Stalker TJ, Wu J, Morgans A, Traxler EA, Wang L, Chatterjee MS, et al. Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo. *J Thromb Haemost*. 2009;7(11):1886–96.
146. Sobocka MB, Sobocki T, Babinska A, Hartwig JH, Li M, Ehrlich YH, et al. Signaling pathways of the F11 receptor (F11R; a.k.a. JAM-1, JAM-A) in human platelets: F11R dimerization, phosphorylation and complex formation with the integrin GPIIb. *J Recept Signal Transduct Res*. 2004;24(1–2):85–105.
147. Naik MU, Caplan JL, Naik UP. Junctional adhesion molecule-A suppresses platelet integrin $\alpha\text{IIb}\beta\text{3}$ signaling by recruiting Csk to the integrin-c-Src complex. *Blood*. 2014;123(9):1393–402.

148. Naik MU, Stalker TJ, Brass LF, Naik UP. JAM-A protects from thrombosis by suppressing integrin $\alpha\text{IIb}\beta\text{3}$ -dependent outside-in signaling in platelets. *Blood*. 2012;119(14):3352–60.
149. Orlowski E, Chand R, Yip J, Wong C, Goschnick MW, Wright MD, et al. A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stability in vivo. *J Thromb Haemost*. 2009;7(12):2074–84.
150. Lau LM, Wee JL, Wright MD, Moseley GW, Hogarth PM, Ashman LK, et al. The tetraspanin superfamily member CD151 regulates outside-in integrin $\alpha\text{IIb}\beta\text{3}$ signaling and platelet function. *Blood*. 2004;104(8):2368–75.
151. Goschnick MW, Lau LM, Wee JL, Liu YS, Hogarth PM, Robb LM, et al. Impaired “outside-in” integrin $\alpha\text{IIb}\beta\text{3}$ signaling and thrombus stability in TSSC6-deficient mice. *Blood*. 2006;108(6):1911–8.
152. Israels SJ, McMillan-Ward EM. CD63 modulates spreading and tyrosine phosphorylation of platelets on immobilized fibrinogen. *Thromb Haemost*. 2005;93(2):311–8.
153. Uchtmann K, Park ER, Bergsma A, Segula J, Edick MJ, Miranti CK. Homozygous loss of mouse tetraspanin CD82 enhances integrin $\alpha\text{IIb}\beta\text{3}$ expression and clot retraction in platelets. *Exp Cell Res*. 2015;339(2):261–9.
154. Indig FE, Diaz-Gonzalez F, Ginsberg MH. Analysis of the tetraspanin CD9-integrin $\alpha\text{IIb}\beta\text{3}$ (GPIIb-IIIa) complex in platelet membranes and transfected cells. *Biochem J*. 1997;327(Pt 1):291–8.
155. Israels SJ, McMillan-Ward EM, Easton J, Robertson C, McNicol A. CD63 associates with the $\alpha\text{IIb}\beta\text{3}$ integrin-CD9 complex on the surface of activated platelets. *Thromb Haemost*. 2001;85(1):134–41.
156. Wright MD, Geary SM, Fitter S, Moseley GW, Lau LM, Sheng KC, et al. Characterization of mice lacking the tetraspanin superfamily member CD151. *Mol Cell Biol*. 2004;24(13):5978–88.
157. Makkawi M, Moheimani F, Alserihi R, Howells D, Wright M, Ashman L, et al. A complementary role for tetraspanin superfamily member CD151 and ADP purinergic P2Y₁₂ receptor in platelets. *Thromb Haemost*. 2015;114(5):1004–19.
158. Makkawi M, Howells D, Wright MD, Jackson DE. A complementary role for tetraspanin superfamily member TSSC6 and ADP purinergic P2Y₁₂ receptor in platelets. *Thromb Res*. 2018;161:12–21.
159. Mangin PH, Kleitz L, Boucheix C, Gachet C, Lanza F. CD9 negatively regulates integrin $\alpha\text{IIb}\beta\text{3}$ activation and could thus prevent excessive platelet recruitment at sites of vascular injury. *J Thromb Haemost*. 2009;7(5):900–2.
160. Saller F, Burnier L, Schapira M, Angelillo-Scherrer A. Role of the growth arrest-specific gene 6 (gas6) product in thrombus stabilization. *Blood Cells Mol Dis*. 2006;36(3):373–8.
161. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. *J Clin Invest*. 2005;115(2):237–46.
162. Gould WR, Baxi SM, Schroeder R, Peng YW, Leadley RJ, Peterson JT, et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. *J Thromb Haemost*. 2005;3(4):733–41.
163. Cosemans JM, Van Kruchten R, Olieslagers S, Schurgers LJ, Verheyen FK, Munnix IC, et al. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. *J Thromb Haemost*. 2010;8(8):1797–808.
164. Law LA, Graham DK, Di Paola J, Branchford BR. GAS6/TAM pathway signaling in hemostasis and thrombosis. *Front Med (Lausanne)*. 2018;5:137.
165. Wannemacher KM, Zhu L, Jiang H, Fong KP, Stalker TJ, Lee D, et al. Diminished contact-dependent reinforcement of Syk activation underlies impaired thrombus growth in mice lacking Semaphorin 4D. *Blood*. 2010;116(25):5707–15.
166. Nanda N, Andre P, Bao M, Clauser K, Deguzman F, Howie D, et al. Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. *Blood*. 2005;106(9):3028–34.
167. Hofmann S, Braun A, Pozgaj R, Morowski M, Vogtle T, Nieswandt B. Mice lacking the SLAM family member CD84 display unaltered platelet function in hemostasis and thrombosis. *PLoS One*. 2014;9(12):e115306.
168. Gong H, Shen B, Flevaris P, Chow C, Lam SC, Voyno-Yasenetskaya TA, et al. G protein subunit Ga13 binds to integrin $\alpha\text{IIb}\beta\text{3}$ and mediates integrin “outside-in” signaling. *Science*. 2010;327(5963):340–3.
169. Moers A, Nieswandt B, Massberg S, Wettschreck N, Gruner S, Konrad I, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. *Nat Med*. 2003;9(11):1418–22.
170. Xiang B, Zhang G, Ye S, Zhang R, Huang C, Liu J, et al. Characterization of a novel integrin binding protein, VPS33B, which is important for platelet activation and in vivo thrombosis and hemostasis. *Circulation*. 2015;132(24):2334–44.
171. Obergfell A, Judd BA, del Pozo MA, Schwartz MA, Koretzky GA, Shattil SJ. The molecular adapter SLP-76 relays signals from platelet integrin $\alpha\text{IIb}\beta\text{3}$ to the actin cytoskeleton. *J Biol Chem*. 2001;276(8):5916–23.
172. Leon C, Eckly A, Hechler B, Aleil B, Freund M, Ravanat C, et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. *Blood*. 2007;110(9):3183–91.
173. Deshmukh L, Gorbatyuk V, Vinogradova O. Integrin β3 phosphorylation dictates its complex with the Shc phosphotyrosine-binding (PTB) domain. *J Biol Chem*. 2010;285(45):34875–84.
174. Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction. $\alpha\text{IIb}\beta\text{3}$ -(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. *J Biol Chem*. 1996;271(18):10811–5.
175. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of Fc γ RIIIa as the ITAM-bearing receptor mediating $\alpha\text{IIb}\beta\text{3}$ outside-in integrin signaling in human platelets. *Blood*. 2008;112(7):2780–6.
176. Takizawa H, Nishimura S, Takayama N, Oda A, Nishikii H, Morita Y, et al. Lnk regulates integrin $\alpha\text{IIb}\beta\text{3}$ outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. *J Clin Invest*. 2010;120(1):179–90.
177. Xu Y, Ouyang X, Yan L, Zhang M, Hu Z, Gu J, et al. Sin1 (stress-activated protein kinase-interacting protein) regulates ischemia-induced microthrombosis through integrin $\alpha\text{IIb}\beta\text{3}$ -mediated outside-in signaling and hypoxia responses in platelets. *Arterioscler Thromb Vasc Biol*. 2018;38(12):2793–805.
178. Tsai HJ, Tseng CP. The adaptor protein Disabled-2: new insights into platelet biology and integrin signaling. *Thromb J*. 2016;14(Suppl 1):28.
179. Tsai HJ, Huang CL, Chang YW, Huang DY, Lin CC, Cooper JA, et al. Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice. *Arterioscler Thromb Vasc Biol*. 2014;34(11):2404–12.
180. Shcherbina A, Cooley J, Lutskiy MI, Benarafa C, Gilbert GE, Remold-O'Donnell E. WASP plays a novel role in regulating platelet responses dependent on $\alpha\text{IIb}\beta\text{3}$ integrin outside-in signalling. *Br J Haematol*. 2010;148(3):416–27.
181. Shen B, Zhao X, O'Brien KA, Stojanovic-Terpo A, Delaney MK, Kim K, et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. *Nature*. 2013;503(7474):131–5.
182. Clements JL, Lee JR, Gross B, Yang B, Olson JD, Sandra A, et al. Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. *J Clin Invest*. 1999;103(1):19–25.
183. Judd BA, Myung PS, Leng L, Obergfell A, Pear WS, Shattil SJ, et al. Hematopoietic reconstitution of SLP-76 corrects hemostasis and platelet signaling through $\alpha\text{IIb}\beta\text{3}$ and collagen receptors. *Proc Natl Acad Sci U S A*. 2000;97(22):12056–61.
184. Zhang H, Berg JS, Li Z, Wang Y, Lang P, Sousa AD, et al. Myosin-X provides a motor-based link between integrins and the cytoskeleton. *Nat Cell Biol*. 2004;6(6):523–31.
185. Donner L, Gremer L, Ziehm T, Gertzen CGW, Gohlke H, Willbold D, et al. Relevance of N-terminal residues for amyloid- β binding to platelet integrin $\alpha\text{IIb}\beta\text{3}$, integrin outside-in signaling and amyloid- β fibril formation. *Cell Signal*. 2018;50:121–30.
186. Verhaar R, Dekkers DW, De Cuyper IM, Ginsberg MH, de Korte D, Verhoeven AJ. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin $\alpha\text{IIb}\beta\text{3}$. *Blood*. 2008;112(13):4935–9.
187. Ghuman H, Shepherd-Roberts A, Watson S, Zuidschewoude M, Watson SP, Voelz K. Mucor circinelloides induces platelet aggregation through integrin $\alpha\text{IIb}\beta\text{3}$ and Fc γ RIIIa. *Platelets*. 2018. <https://doi.org/10.1080/09537104.2017.1420152>.
188. Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ. Heparin promotes platelet responsiveness by potentiating $\alpha\text{IIb}\beta\text{3}$ -mediated outside-in signaling. *Blood*. 2011;117(18):4946–52.
189. Kiouptsi K, Gambaryan S, Walter E, Walter U, Jurk K, Reinhardt C. Hypoxia impairs agonist-induced integrin $\alpha\text{IIb}\beta\text{3}$ activation and platelet aggregation. *Sci Rep*. 2017;7(1):7621.
190. Unsworth AJ, Kriek N, Bye AP, Naran K, Sage T, Flora GD, et al. PPAR γ agonists negatively regulate $\alpha\text{IIb}\beta\text{3}$ integrin outside-in signaling and platelet function through up-regulation of protein kinase A activity. *J Thromb Haemost*. 2017;15(2):356–69.
191. Tseng WL, Huang CL, Chong KY, Liao CH, Stern A, Cheng JC, et al. Reelin is a platelet protein and functions as a positive regulator of platelet spreading on fibrinogen. *Cell Mol Life Sci*. 2010;67(4):641–53.
192. Gowert NS, Kruger I, Klier M, Donner L, Kipkeew F, Gliem M, et al. Loss of Reelin protects mice against arterial thrombosis by impairing integrin activation and thrombus formation under high shear conditions. *Cell Signal*. 2017;40:210–21.

193. Zhao Z, Wu Y, Zhou J, Chen F, Yang A, Essex DW. The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses. *Blood*. 2019;133(3):246–51.
194. Arias-Salgado EG, Lizano S, Shattil SJ, Ginsberg MH. Specification of the direction of adhesive signaling by the integrin β cytoplasmic domain. *J Biol Chem*. 2005;280(33):29699–707.
195. Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, Shattil SJ. Src kinase activation by direct interaction with the integrin β cytoplasmic domain. *Proc Natl Acad Sci U S A*. 2003;100(23):13298–302.
196. Huang J, Shi X, Xi W, Liu P, Long Z, Xi X. Evaluation of targeting c-Src by the RGT-containing peptide as a novel antithrombotic strategy. *J Hematol Oncol*. 2015;8:62.
197. Su X, Mi J, Yan J, Flevaris P, Lu Y, Liu H, et al. RGT, a synthetic peptide corresponding to the integrin $\beta 3$ cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin $\alpha IIb\beta 3$ with Src kinase. *Blood*. 2008;112(3):592–602.
198. Ablooglu AJ, Kang J, Petrich BG, Ginsberg MH, Shattil SJ. Antithrombotic effects of targeting $\alpha IIb\beta 3$ signaling in platelets. *Blood*. 2009;113(15):3585–92.
199. Arias-Salgado EG, Haj F, Dubois C, Moran B, Kasirer-Friede A, Furie BC, et al. PTP-1B is an essential positive regulator of platelet integrin signaling. *J Cell Biol*. 2005;170(5):837–45.
200. Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, et al. Coordinate interactions of Csk, Src, and Syk kinases with $\alpha IIb\beta 3$ initiate integrin signaling to the cytoskeleton. *J Cell Biol*. 2002;157(2):265–75.
201. Bustelo XR. Regulatory and signaling properties of the Vav family. *Mol Cell Biol*. 2000;20(5):1461–77.
202. Pearce AC, McCarty OJ, Calaminus SD, Vigorito E, Turner M, Watson SP. Vav family proteins are required for optimal regulation of PLC $\gamma 2$ by integrin $\alpha IIb\beta 3$. *Biochem J*. 2007;401(3):753–61.
203. Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, et al. Genetic and pharmacological analyses of Syk function in $\alpha IIb\beta 3$ signaling in platelets. *Blood*. 1999;93(8):2645–52.
204. Poole A, Gibbins JM, Turner M, van de Winkel JG, Saito T, et al. The Fc receptor γ -chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. *EMBO J*. 1997;16(9):2333–41.
205. Clark EA, Shattil SJ, Brugge JS. Regulation of protein tyrosine kinases in platelets. *Trends Biochem Sci*. 1994;19(11):464–9.
206. Beck S, Leitges M, Stegner D. Protein kinase C α is dispensable for platelet function in thrombosis and hemostasis in mice. *Cell Signal*. 2017;38:223–9.
207. Yoshioka A, Shirakawa R, Nishioka H, Tabuchi A, Higashi T, Ozaki H, et al. Identification of protein kinase C α as an essential, but not sufficient, cytosolic factor for Ca $^{2+}$ -induced α - and dense-core granule secretion in platelets. *J Biol Chem*. 2001;276(42):39379–85.
208. Tabuchi A, Yoshioka A, Higashi T, Shirakawa R, Nishioka H, Kita T, et al. Direct demonstration of involvement of protein kinase C α in the Ca $^{2+}$ -induced platelet aggregation. *J Biol Chem*. 2003;278(29):26374–9.
209. Buensuceso CS, Obergfell A, Soriani A, Eto K, Kiosses WB, Arias-Salgado EG, et al. Regulation of outside-in signaling in platelets by integrin-associated protein kinase C β . *J Biol Chem*. 2005;280(1):644–53.
210. Pula G, Schuh K, Nakayama K, Nakayama KI, Walter U, Poole AW. PKC δ regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. *Blood*. 2006;108(13):4035–44.
211. Chari R, Getz T, Nagy B Jr, Bhavaraju K, Mao Y, Bynagari YS, et al. Protein kinase C δ differentially regulates platelet functional responses. *Arterioscler Thromb Vasc Biol*. 2009;29(5):699–705.
212. Soriani A, Moran B, de Virgilio M, Kawakami T, Altman A, Lowell C, et al. A role for PKC θ in outside-in $\alpha IIb\beta 3$ signaling. *J Thromb Haemost*. 2006;4(3):648–55.
213. Hall KJ, Harper MT, Gilio K, Cosemans JM, Heemskerk JW, Poole AW. Genetic analysis of the role of protein kinase C θ in platelet function and thrombus formation. *PLoS One*. 2008;3(9):e3277.
214. Maxwell MJ, Yuan Y, Anderson KE, Hibbs ML, Salem HH, Jackson SP. SHIP1 and Lyn kinase negatively regulate integrin $\alpha IIb\beta 3$ signaling in platelets. *J Biol Chem*. 2004;279(31):32196–204.
215. Battram AM, Durrant TN, Agbani EO, Heesom KJ, Paul DS, Piatt R, et al. The phosphatidylinositol 3,4,5-trisphosphate (PI (3,4,5) P $_3$) binder Rasa3 regulates phosphoinositide 3-kinase (PI3K)-dependent integrin $\alpha IIb\beta 3$ outside-in signaling. *J Biol Chem*. 2017;292(5):1691–704.
216. Sun DS, Lo SJ, Lin CH, Yu MS, Huang CY, Chen YF, et al. Calcium oscillation and phosphatidylinositol 3-kinase positively regulate integrin $\alpha IIb\beta 3$ -mediated outside-in signaling. *J Biomed Sci*. 2005;12(2):321–33.
217. Lian L, Wang Y, Draznin J, Eslin D, Bennett JS, Poncz M, et al. The relative role of PLC β and PI3K γ in platelet activation. *Blood*. 2005;106(1):110–7.
218. Cosemans JM, Munnix IC, Wetzker R, Heller R, Jackson SP, Heemskerk JW. Continuous signaling via PI3K isoforms β and γ is required for platelet ADP receptor function in dynamic thrombus stabilization. *Blood*. 2006;108(9):3045–52.
219. Laurent PA, Hechler B, Solinhac R, Ragab A, Cabou C, Anquetil T, et al. Impact of PI3K α (phosphoinositide 3-kinase α) inhibition on hemostasis and thrombosis. *Arterioscler Thromb Vasc Biol*. 2018;38(9):2041–53.
220. Buitrago L, Langdon WY, Sanjay A, Kunapuli SP. Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling. *Blood*. 2011;118(20):5631–40.
221. Cipolla L, Consonni A, Guidetti G, Canobbio I, Okigaki M, Falasca M, et al. The proline-rich tyrosine kinase Pyk2 regulates platelet integrin $\alpha IIb\beta 3$ outside-in signaling. *J Thromb Haemost*. 2013;11(2):345–56.
222. Canobbio I, Cipolla L, Consonni A, Momi S, Guidetti G, Oliviero B, et al. Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca (2+)-dependent tyrosine kinase Pyk2. *Blood*. 2013;121(4):648–57.
223. Laurent PA, Severin S, Hechler B, Vanhaesebroeck B, Payrastre B, Gratacap MP. Platelet PI3K β and GSK3 regulate thrombus stability at a high shear rate. *Blood*. 2015;125(5):881–8.
224. Prevost N, Mitsios JV, Kato H, Burke JE, Dennis EA, Shimizu T, et al. Group IVA cytosolic phospholipase A2 (cPLA2 α) and integrin $\alpha IIb\beta 3$ reinforce each other's functions during $\alpha IIb\beta 3$ signaling in platelets. *Blood*. 2009;113(2):447–57.
225. Wong DA, Kita Y, Uozumi N, Shimizu T. Discrete role for cytosolic phospholipase A (2) α in platelets: studies using single and double mutant mice of cytosolic and group IIA secretory phospholipase A (2). *J Exp Med*. 2002;196(3):349–57.
226. Khatlani T, Pradhan S, Da Q, Shaw T, Buchman VL, Cruz MA, et al. A novel interaction of the catalytic subunit of protein phosphatase 2A with the adaptor protein CIN85 suppresses phosphatase activity and facilitates platelet outside-in $\alpha IIb\beta 3$ integrin signaling. *J Biol Chem*. 2016;291(33):17360–8.
227. Pleines I, Hagedorn I, Gupta S, May F, Chakarova L, van Hengel J, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. *Blood*. 2012;119(4):1054–63.
228. Pleines I, Elvers M, Strehl A, Pozgajova M, Varga-Szabo D, May F, et al. Rac1 is essential for phospholipase C- $\gamma 2$ activation in platelets. *Pflugers Arch*. 2009;457(5):1173–85.
229. Akbar H, Shang X, Perveen R, Berryman M, Funk K, Johnson JF, et al. Gene targeting implicates Cdc42 GTPase in GPVI and non-GPVI mediated platelet filopodia formation, secretion and aggregation. *PLoS One*. 2011;6(7):e22117.
230. Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, et al. Effects of glycoprotein IIb/IIIa antagonists: anti platelet aggregation and beyond. *Curr Drug Metab*. 2016;17(2):194–203.
231. Schwarz M, Nordt T, Bode C, Peter K. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, $\alpha M\beta 2$). *Thromb Res*. 2002;107(3–4):121–8.
232. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. *J Biol Chem*. 1993;268(2):1066–73.
233. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. *Lancet*. 1994;343(8902):881–6.
234. Stoffer K, Shah S. *Abciximab*. StatPearls, Vol. Treasure Island (FL); 2018.
235. De Luca G, Savonitto S, van't Hof AW, Suryapranata H. Platelet GP IIb-IIIa receptor antagonists in primary angioplasty: back to the future. *Drugs*. 2015;75(11):1229–53.
236. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. *Circulation*. 2000;102(2):149–56.
237. Fan P, Gao Y, Zheng M, Xu T, Schoenhagen P, Jin Z. Recent progress and market analysis of anticoagulant drugs. *J Thorac Dis*. 2018;10(3):2011–25.
238. Goodman SL, Picard M. Integrins as therapeutic targets. *Trends Pharmacol Sci*. 2012;33(7):405–12.
239. Xie Z, Cao C, Feng S, Huang J, Li Z. Progress in the research of GPIIb/IIIa antagonists. *Future Med Chem*. 2015;7(9):1149–71.

240. Jamasbi J, Ayabe K, Goto S, Nieswandt B, Peter K, Siess W. Platelet receptors as therapeutic targets: past, present and future. *Thromb Haemost.* 2017;117(7):1249–57.
241. Estevez B, Shen B, Du X. Targeting integrin and integrin signaling in treating thrombosis. *Arterioscler Thromb Vasc Biol.* 2015;35(1):24–9.
242. Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic $\alpha\text{IIb}\beta_3$ (GPIIb/IIIa) antagonists. *Arterioscler Thromb Vasc Biol.* 2007;27(3):e9–15.
243. Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, et al. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. *Circ Res.* 2014;114(7):1083–93.
244. Fuentes RE, Zaitsev S, Ahn HS, Hayes V, Kowalska MA, Lambert MP, et al. A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation. *J Clin Invest.* 2016;126(2):483–94.
245. Hohmann JD, Wang X, Krajewski S, Selan C, Haller CA, Straub A, et al. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? *Blood.* 2013;121(16):3067–75.
246. Liu TD, Ren SH, Ding X, Xie ZL, Kong Y. A short half-life $\alpha\text{IIb}\beta_3$ antagonist ANTP266 reduces thrombus formation. *Int J Mol Sci.* 2018;19(8):2306.
247. Li J, Vootukuri S, Shang Y, Negri A, Jiang JK, Nedelman M, et al. RUC-4: a novel $\alpha\text{IIb}\beta_3$ antagonist for prehospital therapy of myocardial infarction. *Arterioscler Thromb Vasc Biol.* 2014;34(10):2321–9.
248. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in $\alpha\text{IIb}\beta_3$ signalling and platelet function. *Nature.* 1999;401(6755):808–11.
249. Schroeder J, Lullmann-Rauch R, Himmerkus N, Pleines I, Nieswandt B, Orinska Z, et al. Deficiency of the tetraspanin CD63 associated with kidney pathology but normal lysosomal function. *Mol Cell Biol.* 2009;29(4):1083–94.
250. Senis YA, Tomlinson MG, Ellison S, Mazharian A, Lim J, Zhao Y, et al. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. *Blood.* 2009;113(20):4942–54.
251. Wang L, Wu Y, Zhou J, Ahmad SS, Mutus B, Garbi N, et al. Platelet-derived ERp57 mediates platelet incorporation into a growing thrombus by regulation of the $\alpha\text{IIb}\beta_3$ integrin. *Blood.* 2013;122(22):3642–50.
252. Fan X, Wang C, Shi P, Gao W, Gu J, Geng Y, et al. Platelet MEK3 regulates arterial thrombosis and myocardial infarct expansion in mice. *Blood Adv.* 2018;2(12):1439–48.
253. Chen X, Fan X, Tan J, Shi P, Wang X, Wang J, et al. Palladin is involved in platelet activation and arterial thrombosis. *Thromb Res.* 2017;149:1–8.
254. Chen X, Zhang Y, Wang Y, Li D, Zhang L, Wang K, et al. PDK1 regulates platelet activation and arterial thrombosis. *Blood.* 2013;121(18):3718–26.
255. Weng Z, Li D, Zhang L, Chen J, Ruan C, Chen G, et al. PTEN regulates collagen-induced platelet activation. *Blood.* 2010;116(14):2579–81.
256. McCarty OJ, Larson MK, Auger JM, Kalia N, Atkinson BT, Pearce AC, et al. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. *J Biol Chem.* 2005;280(47):39474–84.
257. Sladojevic N, Oh GT, Kim HH, Beaulieu LM, Falet H, Kaminski K, et al. Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets. *Cardiovasc Res.* 2017;113(11):1307–17.
258. Graff J, Klinkhardt U, Westrup D, Kirchmaier CM, Breddin HK, Harder S. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans. *Br J Clin Pharmacol.* 2003;56(3):321–6.
259. Greenberg HE, Wissel P, Barrett J, Barchowsky A, Gould R, Farrell D, et al. Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. *J Clin Pharmacol.* 2000;40(5):496–507.
260. Collen D, Lu HR, Stassen JM, Vreys I, Yasuda T, Bunting S, et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. *Thromb Haemost.* 1994;71(1):95–102.
261. Michaelis W, Turlapaty P, Gray J, Fiske WD, Faulkner E, Kornhauser D, et al. Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects. *Clin Pharmacol Ther.* 1998;63(3):384–92.
262. Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. *J Med Chem.* 1992;35(24):4640–2.
263. Starnes HB, Patel AA, Stouffer GA. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. *Drugs.* 2011;71(15):2009–30.
264. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. *Circulation.* 1998;98(16):1616–21.
265. Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, et al. Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). *Am J Cardiol.* 2009;103(7):917–22.
266. Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LH. Risk factors for stroke after acute coronary syndromes in the orbofiban in patients with unstable coronary syndromes–thrombolysis in myocardial infarction (OPUS-TIMI) 16 study. *Am Heart J.* 2006;151(2):338–44.
267. Wong CK, Newby LK, Bhapker MV, Aylward PE, Pfisterer M, Alexander KP, et al. Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrifiban vs aspirin to yield maximum protection from ischemic heart events postacute cOroNary sYndromes trials. *Am Heart J.* 2007;154(2):313–21.
268. Topol EJ, Easton D, Harrington RA, Amarencu P, Califf RM, Graffagnino C, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. *Circulation.* 2003;108(4):399–406.
269. Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, et al. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. *Am J Cardiovasc Drugs.* 2003;3(2):101–12.
270. Damiano BP, Mitchell JA, Giardino E, Corcoran T, Haertlein BJ, de Garavilla L, et al. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. *Thromb Res.* 2001;104(2):113–26.
271. Savi P, Badorc A, Lale A, Bordes MF, Bornia J, Labouret C, et al. SR 121787, a new orally active fibrinogen receptor antagonist. *Thromb Haemost.* 1998;80(3):469–76.
272. Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. *Am Heart J.* 2000;140(1):81–93.
273. Zhu J, Choi WS, McCoy JG, Negri A, Zhu J, Naini S, et al. Structure-guided design of a high-affinity platelet integrin $\alpha\text{IIb}\beta_3$ receptor antagonist that disrupts Mg²⁺ binding to the MIDAS. *Sci Transl Med.* 2012;4(125):125ra32.
274. Polishchuk PG, Samoylenko GV, Khristova TM, Krysko OL, Kabanova TA, Kabanov VM, et al. Design, virtual screening, and synthesis of antagonists of $\alpha\text{IIb}\beta_3$ as antiplatelet agents. *J Med Chem.* 2015;58(19):7681–94.
275. Ziegler M, Hohmann JD, Searle AK, Abraham MK, Nandurkar HH, Wang X, et al. A single-chain antibody-CD39 fusion protein targeting activated platelets protects from cardiac ischaemia/reperfusion injury. *Eur Heart J.* 2018;39(2):111–6.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://www.biomedcentral.com/submissions)

